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Aim:  To develop an antigen detection based, point-of-care test that will rapidly 
exclude syphilitic infection in patients presenting with genital ulcers. 
 
Materials and Method:  T. pallidum subsp pallidum, Nichols strain, was propagated 
by intra-testicular inoculation of rabbits.  T. pallidum DNA was obtained by 
suspending the testicular extract in ProbeTec lysis buffer followed by heating.  Crude 
DNA was purified and concentrated.  Specific primers were used for the amplification 
of the gene encoding the 31 kDa T. pallidum rare outer membrane porin protein 
(termed “Tromp1”).  The amplified gene was cloned in frame with the pET100/D-
TOPO vector that carries the N-terminal Xpress epitope and polyhistidine fusion tags.  
A screening PCR, restriction digest and DNA sequencing were used to confirm the 
presence of the tromp1 insert.  Isolated plasmid DNA, pET100/D/tromp1 and the 
pET100/D/lacZ (positive control) were transformed into BL21 (DE3) pLysS E. coli 
cells for expression of recombinant Tromp1 and β-galactosidase as fusion proteins.  
SDS-PAGE and Western blot analysis were applied for detection of the recombinant 
proteins.  
 
Results:  The gene encoding the 31 kDa Tromp protein was successfully cloned and 
sequenced. Multiple sequence alignment showed 100% homology between the cloned 
tromp1 gene sequence and its reference sequence. In addition, a screening PCR for 
transformation products and restriction digest of isolated plasmid DNA confirmed the 
presence of the tromp1 insert.  Following gene expression, SDS-PAGE gel analysis 
showed no difference in the banding pattern between IPTG induced and uninduced 
lysates.  The positive control however, showed a bright and distinct band at its 
xv 
 
expected size range of ~121 kDa.  A Western blot and ELISA using specific 
antibodies to the N-terminal Xpress epitope fusion tag confirmed the absence of 
recombinant Tromp1 protein. 
 
Discussion and Conclusion:  The results show that the tromp1 insert was 
successfully cloned and maintained up until the expression  level. However 
expression of recombinant Tromp1 in BL21 (DE3) pLysS E. coli cells, for use as 
antigen in the serodiagnosis of primary syphilis was not achieved, despite several 
attempts to optimize gene expression.  Expression of the positive control gene 




















Syphilis is a sexually transmitted disease caused by the spirochete Treponema 
pallidum subsp pallidum.  This species belongs to the order Spirochaetales, the family 
Spirochaetaceae and the genus Treponema (Tramont EC, 2005).   The genus 
Treponema comprises pathogenic and non-pathogenic species indigenous to human 
and animals (Radolf JD, 1991).  Among the human pathogens, there are four, namely; 
Treponema pallidum subsp pallidum the syphilis-causing agent; Treponema pallidum 
subsp endemicum causes endemic syphilis (bejel); Treponema pallidum subsp 
pertenue causes yaws and Treponema carateum causes pinta (Singh and 
Romanowski, 1999).  T. pallidum subsp pallidum is the “most invasive of the 
pathogenic treponemes” as it “produces highly destructive lesions in almost any tissue 
of the body” (Radolf JD, 1991).   
 
Syphilis begins as an ulcerated lesion termed “chancre” at the site of entry.  If 
untreated, the organism disseminates from its initial site to produce a maculopapular 
rash characteristic of secondary stage syphilis.  The disease may then enter an 
asymptomatic latent stage which may be cleared by the immune system or reappear as 
tertiary stage syphilis with the potential to infect any tissue in the body.   
 
Syphilis was first reported in Europe in the late 15
th
 century.  By the 16
th
 century the 
disease had progressed to become a major public health issue earning its name, “the 
great pox” (Chiu and Radolf, 1994).  Syphilis continued to be an important global 
health problem throughout the 20
th
 and into the 21
st
 century.  In the year 1999, the 
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World Health Organization estimated the occurance of 12 million new cases of 
syphilis, worldwide, most of which occurred in the developing countries (World 
Health Organization, 2001).  It has been reported that syphilis occurs mainly among 
the poor, those who lack access to health care as well as those who have multiple 
sexual partners (Peeling and Hook, 2006).   
 
The introduction of penicillin therapy in the late 1940s along with improved 
preventive measures and the implementation of STI control programs resulted in 
reduction of the levels of syphilis over the years.  In addition, due to the scarce 
laboratory facilities for diagnosing GUD in resource-poor settings, a syndrome-based 
approach to the management of STIs had been introduced and implemented across 
several developing countries.  The syndromic management approach is based on the 
identification of a syndrome i.e. a group of symptoms a patient complains of along 
with easily recognizable signs upon clinical examination.  If an STI syndrome is 
identified, combination treatment is provided that covers the majority of organisms 
responsible for that syndrome in a particular geographical area (Altini and Coetzee, 
2005).   
 
Till the development of PCR based tests, the inability to cultivate T. pallidum in vitro, 
or to sustain the organism in cell culture through multiple generations, has made it 
difficult to obtain a definitive diagnosis of syphilis.   Furthermore, a specimen source 
from the latent and late stages cannot be obtained, since lesions are absent (Karp et 
al., 2009).  Clinical symptoms, the identification of treponemes in lesion exudate and 
antibody detection tests form the basis for diagnosing syphilis.  Darkfield microscopy 
can detect motile treponemes within exudate obtained from lesions of patients with 
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primary, secondary or early congenital syphilitic infection. It is at these stages of a 
syphilitic infection that treponemes in the lesions are in abundance and darkfield 
examination is most successful. However, T. pallidum subsp pallidum cannot be 
distinguished from the other pathogenic subspecies by means of microscopy 
(Ceighton ET, 1990; Larsen et al., 1995). Furthermore, darkfield microscopy is not 
suitable for examining specimens obtained from oral and anal lesions due to the 
difficulty in distinguishing T. pallidum from commensal treponemes present in these 
cavities (Chiu and Radolf, 1994; Ryan KJ, 2004).   In addition, darkfield microscopy 
requires laboratory skill and experience to perform.  Therefore, in parts of the world 
where this is feasible, PCR has replaced darkfield microscopy. 
 
Serological tests provide a more practical method for diagnosing syphilis and are the 
only means for identifying asymptomatically infected persons (Radolf JD, 1991).  
Serological tests for syphilis fall into two categories: nontreponemal and treponemal 
tests.   
 
Nontreponemal tests (VDRL and RPR) detect antibodies to a combination of 
cardiolipin, cholesterol and lecithin. These antibodies are however not exclusive to 
patients with T. pallidum infection as these may test positive for other treponemal 
diseases and nontreponemal diseases involving tissue damage and a variety of 
autoimmune diseases (Ryan KJ, 2004).  Hence, a reactive nontreponemal test itself 
cannot confirm a T. pallidum infection. 
 
Treponemal tests (TPHA and FTA-ABS) are more specific to T. pallidum since they 
detect antibodies to specific T. pallidum antigens (Ryan KJ, 2004).  They are therefore 
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used to confirm reactive nontreponemal tests of presumed syphilitic patients.  Unlike 
the nontreponemal tests, they cannot be used for assessment of response to treatment 
because antibodies to treponemal antigens can persist for years. Hence, test results 
remain positive for years, if not for life (World Health Organization, SDI, 2006; Ryan 
KJ, 2004).  However they can be used as screening tests since treponemal tests are 
only falsely reactive in approximately 1% of the general population (Goldman and 
Lantz, 1971).  Treponemal tests are costly and technically more difficult to perform 
than nontreponemal tests.  Furthermore treponemal tests take at least 1-2 hours or 
more to obtain results, which is longer than with nontreponemal tests. 
 
In this study we aimed to develop a rapid point-of-care test that uses immobilized 
specific antibody to detect whole treponemes in primary ulcer secretions.  The test 
was planned to be an immunochromatographic (IC) test strip incorporating specific 
antibodies raised against the 31 kDa T. pallidum rare outer membrane porin protein.  
Performing such a test, requires only a minimum of technical training, can be 
performed within minutes at room temperature and does not require the use of any 
equipment.   
 
While T. pallidum once used to be among the leading bacterial causes of genital ulcer 
disease (GUD) in African and other developing countries, it has now been superceded 
by herpes simplex virus type 2 (HSV-2) infection, as recent studies in Africa have 
shown (Nilsen et al., 2007; Mwansasu et al., 2002; Ahmed et al., 2003; Moodley et 
al., to be published).  With decreasing levels of syphilis, it is not surprising that 
patients presenting with genital ulcer syndrome, most often suffer from another 
sexually transmitted infection.  Despite this, patients are treated for syphilis as well, 
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since it is included in the syndromic management guidelines for genital ulcer 
syndrome.  The “unnecessary” treatment with penicillin for syphilis does result in 
hypersensitivity reactions and may hypothetically result in the development of 
resistance in T. pallidum and other bacterial species.  For this reason, the proposed 
rapid point-of care test is aimed to exclude the possibility of a syphilitic infection 
when used to diagnose individuals presenting with genital ulcers.  Overall, this will 
































(2.1)  The Genus Treponema 
 
Treponema pallidum subspecies pallidum is the causative agent of venereal syphilis. 
This species belongs to the order Spirochaetales, the family Spirochaetaceae and the 
genus Treponema (Tramont EC, 2005).  The genus Treponema comprises pathogenic 
and non-pathogenic species indigenous to human and animals (Radolf JD, 1991).  
Among the human pathogens, there are four, namely; Treponema pallidum subsp 
pallidum, the syphilis-causing agent; Treponema pallidum subsp endemicum causes 
endemic syphilis (bejel); Treponema pallidum subsp pertenue causes yaws and 
Treponema carateum causes pinta (Radolf JD, 1991; Norris and Larsen, 1995).   
 
T. pallidum subsp pallidum is the “most invasive of the pathogenic treponemes” as it 
“produces highly destructive lesions in almost any tissue of the body” (Radolf JD, 
1991).  “T. pallidum subsp pertenue and endemicum are intermediate in invasiveness” 
causing destructive lesions in only bones and soft tissue.  T. carateum is the least 
invasive species causing only cutaneous disease (Radolf JD, 1991).  These pathogenic 
treponemes are closely related in their morphology, their antigenic structure, by DNA 
homology and by their ability to adhere to mammalian cells.  Furthermore, no 
metabolic, structural or virulence marker differences among the pathogenic 
treponemes have been found and their antigenic relatedness results in similar 
seropositive outcomes among patients infected with all pathogenic treponemes 
(Tramont EC, 2005).  Despite the fact that all of the species are closely related in 
many ways, they do express immunological differences as shown in rabbit models in 
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which experimental treponematosis infection by one species induced complete 
protection against reinfection by the homologous species, but only partial protection 
against heterologous species.  In addition, although there is no established reason for 
this, they cause distinctly different diseases (Tramont EC, 2005).  Also differences are 
noted in the host range, modes of transmission and geographic distribution which 
assists in speciation and subspeciation (Chiu and Radolf, 1994).   
 
Several non-pathogenic species have also been identified in humans.  These are found 
in particular as part of the normal flora of the intestinal tract, the oral cavity and 
genitalia of male and female (Radolf JD, 1991).  Treponema paraluiscuniculi is the 
only known animal pathogen among the treponema species (Chiu and Radolf, 1994).   
 
 
(2.2)  Historical Background of Syphilis 
 
 
The origin of syphilis has been debated over the centuries, following its emergence in 
Europe in the late 15
th
 century, coinciding with the return of Christopher Columbus 
from the New World.  Three main theories have been proposed:  the Columbian 
theory; the pre-Columbian theory and the mutation/virulence theory.  The Columbian 
theory suggests that syphilis was imported from the New World by Christopher 
Columbus and his crew and then spread by mercenaries in the army of Charles VIII of 
France during his siege of Naples (Chiu and Radolf, 1994).  The pre-Columbian 
theory on the other hand states that syphilis was well-established in Europe before the 
return of Columbus but had been confused with other diseases of similar 
symptomatology, such as leprosy (Baskan and Tunali, 2002).  According to the 
mutation/virulence theory, syphilis has evolved out of jaws, a disease originating in 
Africa. Jaws is caused by Treponema pertenue. The earliest cases of jaws have been 
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described nearly 4400 years earlier than the first syphilis cases (Baskan and Tunali, 
2002).  The mutation/virulence theory postulates that T. pertenue became more 
virulent due to mutational events and became T. pallidum causing syphilis. These 
mutational events could perhaps have taken place in the New World. Columbus and 
his crew may have possibly brought this virulent strain from the New World, and due 
to the lack of resistance in the Europeans, it resulted in a rapid spread of the disease 
(Baskan and Tunali, 2002). 
 
However, the disease had been established and became recognized as a distinct STD 
by the end of the 15
th
 century.   By the 16
th
 century, syphilis had reached epidemic 
proportions in Europe and eventually spread across the world, earning its name “the 
great pox”.  It then became highly endemic in all levels of European society (Chiu and 
Radolf, 1994).  By the mid-19
th
 century, “the cause, epidemiology and clinical 
manifestations of syphilis” had been established (Richord PH, 1842; Tramont EC, 
2005).  By the end of the 19
th
 century, syphilis was perceived as an “imitator” since it 
could mimic the effects of other diseases (Baskan and Tunali, 2002).  Syphilis 
continued to be an important global health problem throughout the 20
th
 and into the 
21
st
 century.  By the 20
th
 century important milestones in syphilis research had been 
achieved.  In 1905, Schaudinn and Hoffman discovered the Treponema pallidum 
spirochete and its association with syphilis (Schaudinn and Hoffman, 1905; Singh and 
Romanowski, 1999; Chiu and Radolf, 1994).  They demonstrated the presence of 
“spirochetes in Giemsa-stained smears of fluid from secondary syphilitic lesions” 
(Schaudinn and Hoffman, 1905; Singh and Romanowski, 1999). The year 1906 saw 
the development of the first serodiagnostic test for syphilis by August von 
Wasserman.  This paved the way for the development of other serologic tests for 
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diagnosing syphilis (Singh and Romanowski, 1999; Wassermann et al., 1906).  
During the same year, Paul Ehrlich made his discovery of the first treatment for 
syphilis in the form of an arsenic containing compound (Tramont EC, 2005).  In the 
1940s, the efficacy of penicillin was demonstrated when Mahoney and colleagues 
(1943) had successfully treated the first four patients with primary syphilis using 
pencillin (Singh and Romanowski, 1999; Mahoney et al., 1943).   Today pencillin 
continues to remain the drug of choice for therapy of all stages of syphilis and no 
resistance to the drug appears to have developed (Chiu and Radolf, 1994). 
 
(2.3)  Epidemiology of Syphilis 
 
In 1947, in the United States, the incidence of primary and secondary syphilis was 
66.4 cases per 100 000 population.  By 1956, these rates had declined to 3.9 cases per 
100 000 (Nakashima et al., 1996; Kilmarx and St. Louis, 1995).  This was attributed 
to the availability of penicillin therapy, changes in sexual behavior and improved 
preventive measures.  However since the 1950’s the United States has had successive 
epidemics with peaks at approximately every 10 years.  There has been an overall 
increase in the maximum rates during these epidemics.  In the last major epidemic, the 
rates peaked in 1990 at 20.3 per 100 000 population, the highest rate since 1949 
(Kilmarx and St. Louis, 1995).  This was largely related to crack cocaine usage and 
the exchange of illegal drugs for sex.  During the 1990’s a national elimination 
program was initiated which had reduced the syphilis incidence rates to the lowest 
level recorded i.e. a rate of 2.5 cases per 100 000 population in the year 1999. 
(MMWR, 2001-a).  However, this was not long lasting.  Since the year 2000, the 
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number of syphilis cases, in the United States increased once again, mainly among 
men who have sex with men (MMWR, 2001-b, 2002 and 2003).   
 
The World Health Organization estimated that 12 million new cases of syphilis had 
occurred worldwide in 1999 (Figure 1), most of which occurred in the developing 
countries (World Health Organization, 2001).  It has been reported that syphilis 
occurs mainly among the poor and those who lack access to health care as well as 
those who have many sexual partners (Peeling and Hook, 2006).   
 
 
In South Africa, syphilis prevalence over the period 1997 to 2008, has shown a 
downward trend as was reported in the 2008 National Antenatal Sentinel HIV and 
Syphilis Prevalence Survey.  The survey investigated syphilis prevalence among 
antenatal clinic attendees in South Africa (Figure 2).  The results showed a decrease 
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among pregnant women presenting at public antenatal care clinics from more than 
10% in 1997 to 1.9% in 2008.  
 
Figure 2:  National syphilis prevalence trends among antenatal women, South Africa, 
1997 to 2008 (National Department of Health, South Africa Report, 2008) 
 
The syphilis prevalence among antenatal women by province in South Africa was also 
determined in the survey, for the period 2006 to 2008 (Table 1).  In 2008, the 
Northern Cape showed with 6.8% the highest prevalence.  This province has had high 
prevalences for the past three years: 6.9% in 2006, 5.4% in 2007 and 6.8% in 2008.  
Western Cape showed a significant increase in syphilis prevalence from 1.9% in 2006 
to 5.6% in 2007 (the highest prevalence by province in South Africa recorded in that 
year).  However, it decreased considerably to 3.8% in 2008.  Similarly, Gauteng, 
Mpumalunga, Eastern Cape, North West and Limpopo all showed an increase in 
prevalence from 2006 to 2007, followed by a significant reduction by 2008.  Only 
Kwazulu-Natal showed a continuous reduction in syphilis amongst first time antenatal 
clinic attendees from 2006 through to 2008 (1.0 in 2006, 0.8 in 2007 and 0.6 in 2008).  
In Free State the prevalence remained at 2.5% from 2006 to 2007 but declined slightly 
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to 2.3% in 2008.  Northern Cape was the only province which showed an increase in 
prevalence in 2008 (National Department of Health, South Africa Report, 2008).  
 
Table 1:  Syphilis prevalence by province among first time antenatal attendees in 
South Africa from 2006 to 2008 (National Department of Health, South Africa 
Report, 2008) 
The survey also looked at syphilis prevalence trends among first time antenatal 
attendees by age group for the years 2006 to 2008 (Figure 3).  The results showed a 
decrease in prevalence from 2007 to 2008 in all age groups.  
 
Figure 3:  Syphilis prevalence trends among antenatal women by age group, South 
Africa, 2006 to 2008 (National Department of Health, South Africa Report, 2008). 
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One of the manifestations of STIs is genital ulcer disease (GUD). Genital ulcer 
disease can be the result of either bacterial or viral causative agents.  Among the 
bacterial causes of GUD is T. pallidum which along with H. ducreyi (the cause of 
chancroid), used to be among the leading etiological agents of GUD, representing 
70% - 90% of cases (Pham-Kanter et al., 1996).  However since the late 1980s the 
situation has markedly changed so that the relative importance of T. pallidum and H. 
ducreyi decreased significantly, whereas that of herpes simplex virus type 2 (HSV-2) 
increased. 
 
Several researchers reported on the etiology of GUD in Africa. Most studies applied 
PCR techniques on secretions obtained from genital ulcers. These studies confirmed 
the decreasing prevalence of T. pallidum and H. ducreyi with a significant increase in 
HSV-2 prevalence.   
 
A cohort study conducted by Moodley et al, reported on the trends in the etiology of 
GUD in Durban, South Africa from the period, 1984 until 2004 (to be published).  
This study recruited GUD patients attending the largest clinic in Durban.  “This 20-
year period saw the introduction of syndromic management, the unfolding of the HIV 
epidemic and the introduction of improved diagnostics test systems” (Moodley et al.).  
The results showed that syphilis, chancroid and granuloma inguinale dominated 
during the first decade but decreased over time to be superceded by increasing 
prevalence in genital herpes, LGV and ulcers without diagnosis, in the later years.  
Similar trends were observed in HIV-infected and HIV-uninfected patients (Figure 4), 
with the exception of genital herpes.  Genital herpes was the only disease that showed 
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a consistently higher prevalence in HIV-infected patients, indicating an association 
between this increase and HIV-1 infection (to be published).  
 
Figure 4:  Trends in the aetiology of genital ulcer disease in HIV-1 infected and 
uninfected patients in KwaZulu-Natal for the period, 1995 to 2004 (Moodley et al., to 
be published) 
 





















































































































In a more recent study conducted on 301 patients with GUD in Dar es Salaam, 
Tanzania (2006), the authors reported the following figures: HSV-2 represented 83% 
of all identified pathogens, HSV-1 8%, T. pallidum 4% and H. ducreyi 5% (Nilsen et 
al., 2007).  This study among others (Chen et al., 2000, Lai et al., 2003), confirmed 
the decreasing levels of the bacterial causes of GUD with T. pallidum displaying the 
lowest prevalence recorded for that year.   
 
The downward trend in bacterial causes of GUD has been attributed to effective 
implementation of syndromic management in public health facilities.  Syndromic 
management for GUD does not include treatment for genital herpes.  In addition, the 
awareness of HIV infection and hence the adoption of safer sexual practices may have 
further contributed to the decline.  
 
(2.4)  Structure and Morphology of T. pallidum 
 
T. pallidum is a slim (0.15 µm), helical spirochete measuring 5 to 15 µm in length 
with regular spirals of a wavelength of 1 µm and an amplitude of about 0.3 µm 
(Sherris JC, 2004 and Ryan KJ, 2004).  T. pallidum stains poorly with aniline dyes.  
However it can be readily seen by immunofluoresence darkfield microscopy or silver 
impregnation histologic techniques (Sherris JC, 2004).  Viable T. pallidum “exhibits 
characteristic motility that consists of rapid rotation about its longitudinal axis and 
bending, flexing, and snapping about its full length” (Radolf JD, 1991). 
 
Similarly with all spirochetes, T. pallidum consists of an outer membrane surrounding 
the periplasmic space, a peptidoglycan-cytoplasmic membrane complex, a protoplasm 
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cylinder and endoflagella (Radolf et al., 1995).  Because of this double-membrane 
ultrastucture, T. pallidum has been classified as a gram negative bacterium like E. coli 
(Radolf et al., 1995).  However several studies conducted by Radolf and colleagues 
have shown substantial differences between the outer membrane of T. pallidum and 
that of E. coli.  They demonstrated that the outer membrane of T. pallidum lacks 
lipopolysaccharide (LPS), is far more fragile and appears to have a lower protein/lipid 
ratio when compared to the outer membrane of conventional gram negative bacteria.  
Furthermore its flagella (organelles of motililty) are located within the periplasmic 
space and not extracellulary as with conventional gram negative bacteria (Chiu and 
Radolf, 1994). Hence, these are named endoflagella.  
 
The low protein/lipid content provides a possible explaination as to why specific 
antibodies present in sera from syphilis patients bind poorly to viable T. pallidum.  
This was initially attributed to a protective capsule or outer coat of proteins and 
mucopolysaccharides obtained from the host and located external to the organism’s 
outer membrane (Chiu and Radolf, 1994).  However freeze-fracture and deep-etch 
electron microscopy studies by Radolf and colleagues proved that the poor antibody 
binding of T. pallidum was a result of “a paucity of integral membrane proteins” 
(Radolph et al., 1995) with only some of these proteins extending through the outer 
membrane to become surface exposed.  Freeze-fracture electron microscopy has been 
instrumental in understanding the molecular architecture of the T. pallidum outer 
membrane.  This technique visualizes proteins within cleaved lipid bilayers as being 
intramembranous particles (IMPs). Upon examination of the T. pallidum outer 
membrane, it revealed 100-fold less intramembranous particles as compared to 
conventional gram negative bacteria and that these particles are of uniform size 
17 
 
suggesting only a few different protein species present in the outer membrane (Radolf 
et al., 1995).  In contrast, fracture faces through the cytoplasmic membrane showed a 
greater particle density than its corresponding face of the outer membrane. It was 
estimated that the cytoplasmic membrane of T. pallidum has a ten fold greater density 
than the outer membrane.  In addition, cytoplasmic membrane particles are randomly 
distributed and heterogenous in size thus suggesting a diversity of proteins.  These 
studies reported that the bacterium’s most immunogenic proteins are lipoproteins that 
are anchored to the cytoplasmic membrane thus rendering them inaccessible to 
antibodies directed against these molecules.   
 
Because of this low density of membrane spanning proteins, these have been termed 
“Tromps”, treponemal rare outer membrane proteins (Blanco et al., 1990).  It has 
been suggested that the low density of surface exposed protein antigens may permit  
T. pallidum to evade host immune defenses, thereby contributing to the pathogenesis 
of the organism (Radolf et al., 1995).    
 
(2.5)  Transmission of T. pallidum 
 
Transmission of syphilis occurs mainly by sexual intercourse with an individual who 
has primary or secondary syphilitic lesions.  Late disease is however not infectious 
(Sherris JC, 1984).  Other forms of sexual activity such as kissing, oral-genital and 
oral-anal contact may also transmit infection.  Moreover, body fluids such as urine 
and semen may also harbor treponemes.  Nonsexual modes of transmission such as 
blood transfusions, accidental direct inoculation and the sharing of needles among 
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intravenous drug users may also occur but are thought to be rare (Chiu and Radolf, 
1994).  
 
Transplacental transmission to the developing fetus may occur at any time during 
pregnancy, giving rise to “congenital syphilis”, which is analogous to secondary 
syphilis in the adult (Ryan KJ, 2004).  Perinatal infection may also occur when the 
newborn comes into contact with an infectious lesion or through inoculation with 
maternal blood at the time of delivery (Chiu and Radolf, 1994).   
 
(2.6)   Pathogenesis of T. pallidum 
 
Due to the inability to grow T. pallidum in vitro, it is difficult to obtain sufficient 
numbers of organisms to perform studies. Therefore, the mechanisms involved in the 
pathogenesis of syphilis are not clearly understood.  Current information into the 
pathogenesis of the organism is based on observations of human disease and 
experiments conducted in animal (rabbit) models.    
 
From these observations, it is presumed that T. pallidum enters its human host through 
small breaks in the skin or through penetration of intact mucous membranes where it 
slowly multiplies with little initial tissue reaction.  It produces a lesion at the point of 
entry known as the chancre.  In women, the lesion may occur “on the labia, the walls 
of the vagina or the cervix” (Radolf JD, 1991).  In men, it occurs “on the shaft or 
glans of the penis” (Radolf JD, 1991).  A chancre may also occur on the lips, tongue, 




Microscopically, syphilis is characterised by endarteritis. Endothelial cells within 
small arterioles, swell and proliferate, causing a reduction in local blood supply which 
further results in necrosis. The ulcerated primary lesion is termed the “chancre” which 
contains large amounts of spirochetes.  Endarteritis is also accompanied by the 
infiltration of lympocytes, monocytes and plasma cells at the site of infection (Ryan 
KJ, 2004).   
 
Experiments conducted both on humans and rabbits using standard inocula, have 
shown that fewer than ten spirochetes are capable of causing infection (Chiu and 
Radolf, 1994).  Animal studies have further demonstrated the potential of the 
organisms to appear within minutes in the lymph nodes and their ability to 
disseminate widely within hours (Cumberland and Turner, 1949; Raiziss and Severac, 
1937).   
 
Mechanisms describing the entry of T. pallidum into cells is still unclear.  However, 
in vitro studies have demonstrated the organism’s ability to attach to mammalian cells 
(Fitzgerald et al., 1975; Hayes et al., 1977).  In addition, these studies showed rapid 
invasion of cells, following minutes after cell inoculation. The authors suggest that the 
organism’s desire to enter cells may be an attempt to escape from an unfavourable 
environment.  Alternatively, there may be a specific stage in treponemal growth that 
requires an intracellular residence (Fitzgerald et al., 1975).   Further in vitro studies 
have revealed that T. pallidum may contain receptors on its surface specific for 
fibronectin and other extracellular matrix components thus mediating treponemal 
attachment (Chiu and Radolf, 1994).  It has also been suggested that attachment may 
occur via specific attachment ligands which may serve as potential vaccine candidates 
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(Baseman and Hayes, 1980; Thomas et al., 1985).  It has also been demonstrated that 
T. pallidum attaches to various mammalian tissue culture cell lines in vitro including 
lines derived from genitourinary epithelia, a property not shared by nonpathogenic 
treponemes (Chiu and Radolf, 1994).   
 
An important feature of T. pallidum infection is its ability to disseminate away from 
its initial site of entry.  To accomplish this, the organisms must be able to move 
through the viscous extracellular connective tissue matrix (ECM) that occurs between 
tissue cells (Radolf JD, 1991).  According to Radolf, T. pallidum produces an enzyme 
that can degrade hyaluronic acid which is a major component of ECM (Radolf JD, 
1991).  Hematogenous dissemination occurs as well.  This results in the organisms 
invasion of various organ systems, presumably by penetrating the endothelial cells 
lining small blood vessels (Chiu and Radolf, 1994).  In vitro studies using cultured 
human endothelial cells have shown that T. pallidum rapidly traverses “between tight 
endothelial cell junctions”, indicative of its invasive properties (Chiu and Radolf, 
1994).  It suggests that tissue invasion may be a critical virulence factor for the 
organism. 
 
There is a general belief that the organisms motility greatly contributes towards its 
invasiveness.  The invasiveness of T. pallidum is best observed in congenital syphilis, 
where T. pallidum is one of few bacterial pathogens of humans capable of traversing 
the tissue barriers separating mother and fetus.  Congenital infection occurs mainly by 
transplacental invasion, however other routes of fetal infection such as passage 




(2.7)  Physiology -  Growth and Metabolism 
 
“Most of our knowledge of the physiology, metabolism and antigenic structure of     
T. pallidum is derived from the Nichols strain which has been maintained in rabbits 
since 1912” (Singh and Romanowski, 1999; Nichols and Hough, 1913).  T. pallidum 
cannot survive and multiply outside the mammalian host (Lafond and Lukehart, 
2006).  Its infectious capability is lost within a few hours.  Limited replication has 
been obtained with careful control of oxygen tension and pH in primary tissue culture 
systems, where Fieldsteel and colleagues were able to achieve 100-fold multiplication 
through several generations (Lafond and Lukehart, 2006; Fieldsteel et al., 1981; 
Fieldsteel et al., 1982; Ryan KJ, 2004).  However, T. pallidum subsp pallidum cannot 
be cultured continously in vitro.  Instead it has to be propagated by intra-testicular 
inoculation of rabbits to obtain a sufficient number of organisms for research and 
diagnostic purposes. 
 
T. pallidum multiplies by longitudinal, binary fission with a generation time of about 
30 to 33 hours in vivo (Chiu and Radolf, 1994) and 30 to 50 hours in vitro (Lafond 
and Lukehart, 2006; Fraser et al., 1998).  There are several factors that may contribute 
to the organism’s slow replication rate.  Firstly, T. pallidum has limited metabolic 
capacity.  It lacks the tricarboxylic acid cycle and the electron transport chain related 
to that.  Hence it depends solely on glycolysis for the synthesis of ATP (Lafond and 
Lukehart, 2006; Fraser et al., 1998).  Glycolysis produces a net yield of 2 ATP 
molecules as compared to an organism that undergoes aerobic respiration (eg. E. coli) 
and produces 38 ATP molecules resulting in a 19 times greater energy production per 
substrate equivalent as compared to that of T. pallidum.  T. pallidum’s limited 
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metabolic capacity is explained by the bacterium’s small genome size of 900 kilobase 
pairs, making it one of the smallest prokaryotic genomes (Chiu and Radolf, 1994).  
On analysis of its genome, it indicates that there is an absence of pathways for the 
utilization of alternative carbon sources for energy and de novo synthesis of enzymes 
and nucleotides (Fraser et al., 1998).  Furthermore, it lacks pathways for the synthesis 
of amino- and fatty acid, but carries the necessary enzymes required for 
interconversion of amino acid and fatty acids.  Hence, it has been suggested that with 
the aid of specific transporters, the organism derives essential macromolecules from 
its host and then uses interconversion pathways to generate others (Fraser et al., 
1998).   
 
Secondly, T. pallidum is microaerophilic and requires low levels of free oxygen (2 to 
10%) (Sherris JC, 1984).  Its sensitivity to oxygen is explained by the fact that            
T. pallidum lacks the enzymes catalase and superoxide dismutase, that detoxify 
reactive oxygen species (Fraser et al., 1998).  It is suggested that the organism derives 
protection against oxygen radicals from its host cells (Cox CD, 1983; Cox et al., 
1990). 
 
Thirdly, T. pallidum is unstable at high temperatures as demonstrated by Julius 
Wagner von Jauregg in 1918, whereby he used heat therapy to treat for late 
neurosyphilis.  Patients were inoculated with malaria-infected blood and later treated 
with quinine.  This regimen resulted in elevated body temperature which appeared to 
have destroyed T. pallidum in the central nervous system.  Similar effects were 
observed when alternative methods for raising body temperature were used (Wagner 
von Jauregg J, 1918; Lafond and Lukehart, 2006).  Other conditions such as cold, 
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dessication as well as a wide range of detergents and disinfectants also inactivates the 
T. pallidum organism (Ryan KJ, 2004).   
 
(2.8)  Syphilis in Humans – Clinical Manifestations 
 
 
The clinical manifestations of syphilis in an untreated individual is divided into 
several stages: 
 
(2.8.1)  Primary Syphilis 
 
 
The first clinical manifestation of syphilis is a lesion that develops at the site of entry.  
It begins as an indurated, painless papule that progresses over one to several weeks to 
form an ulcer.  The ulcer when fully developed with a clean, firm base and round 
discrete borders is termed the chancre (Chiu and Radolf, 1994) and can vary in size 
from a few millimetres to more than 2 cm (Ryan KJ, 2004).  Following exposure, the 
primary chancre may develop on average after 3 weeks, with an incubation period 
ranging between 10 to 90 days (U.S. Department of Health, Education, and Welfare, 
1968).  The size of the inoculum determines the development of the lesion.  The 
larger the inoculum size, the more rapid the lesion will develop.  The primary chancre 
is highly infectious and full of spirochetes (Ryan KJ, 2004) thus making the primary 
stage a highly infectious stage.   
 
In heterosexual males, chancres commonly occur on the penis or in the oral cavity. In 
homosexual males lesions can be localized in the rectum and anal canal.  In women, 
chancres usually occur on the vulva, labia or cervix (Ryan KJ, 2004).  Due to these 
inconspicuous locations in both women and homosexual men, primary chancres are 
not always apparent.  Furthermore they are painless. Hence the diagnosis of syphilis 
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may be delayed until further disease manifestations are identified (Lafond and 
Lukehart, 2006).  Diagnosis of syphilis can also prove complicated when chancres are 
not of its classic morphology.  Non-indurated chancres with “irregular borders” have 
been observed (Chapel TA, 1978).  If untreated, the lesion heals spontaneously after 4 
to 6 weeks.  However, in approximately 15% of patients, the lesion may remain 
present at the onset of secondary syphilis.   
 
 








Figure 5:  A syphilitic chancre on the glans penis.  Corey, L.  (1984)  Sexually 
transmitted diseases p. 637-643. In Sherris, J.C. (ed.) Medical microbiology, An 



















Figure 6:  “Kissing” syphilitic chancres on the labia minora.   Chiu and Radolf  
(1994)  Syphilis p. 694-714. In Hoeprich et al., (ed.) Infectious diseases, A treatise of 
infectious processes, 5
th













Figure 7:  Chancre on the tongue.  Chiu and Radolf  (1994)  Syphilis p. 694-714. In 
Hoeprich et al., (ed.) Infectious diseases, A treatise of infectious processes, 5
th
 ed. J.B. 
Lippincott Company, Philadelphia 
 
 
(2.8.2)  Secondary Syphilis 
 
Two to eight weeks following the appearance of the chancre, clinical manifestations 
of secondary stage syphilis begin to appear.  This stage results from the multiplication 
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and dissemination of T. pallidum from its initial site of infection to other host tissues 
(Ryan KJ, 2004).  The most characteristic symptom of secondary syphilis is a 
widespread mucocutaneous rash.  The rash is characterized by pale, distinct lesions 
that are distributed on the trunk and extremeties including the palms, soles and face 
(Lafond and Lukehart, 2006).  The lesions can be described as macular, 
maculopapular, papular, papulosquamous and pustular, with macular and 
maculopapular lesions predominating (Chiu and Radolf, 1994; Lafond and Lukehart, 
2006).  The lesions are symmetric, varying from several millimetres to several 
centimetres in diameter (Chiu and Radolf, 1994).  Other manifestations of secondary 
syphilis include generalized nontender lymph node enlargement accompanied by 
fever, malaise and other manifestations of systemic infection (Ryan KJ, 2004).   
 
Other mucocutaneous manifestations of secondary syphilis include patchy alopecia 
and thinning of the eyebrows and beard, diffuse redness of the tonsils and pharynx as 
well as superficial ulcers of the oral and genital mucosa.  In addition, 10% of patients 
develop painless, mucosal warty erosions called condylomata lata in warm, moist 
areas such as the genitalia and perineum (Chapel TA, 1980; Mindel et al., 1989). 
 
Secondary syphilitic lesions are full of spirochetes and thus highly infectious (Ryan 
KJ, 2004).  If untreated, the lesions heal over several weeks but may be accompanied 
by scarring or hyper- or hypopigmentation.  In the majority of cases however, healing 
occurs without scarring (Singh and Romanowski, 1999).    Secondary infection gets 
resolved in only one third of untreated patients via host immune responses.  In the 





Some Clinical Manifestations of Secondary Stage Syphilis 
 
Figure 8:  (A) Papulosquamous rash of secondary syphilis; (B) Papulosquamous 
lesions of palms and soles characteristic of secondary syphilis.  Chiu and Radolf  
(1994) Syphilis p. 694-714, In Hoeprich et al., (ed.) Infectious diseases, A treatise of 
infectious processes, 5
th















Figure 9:  Condylomata lata, characteristic of secondary syphilis.  Corey, L.  (1984)  
Sexually transmitted diseases p. 637-643, In Sherris, J.C. (ed.) Medical microbiology, 




(2.8.3)  Latent Syphilis 
 
During latent syphilis there are no clinical signs or symptoms or abnormalities in the 
CSF, however serologic test results are positive.  It comprises two stages: early latent 
syphilis and late latent syphilis, based upon the approximation of the time of 
infection.   
 
Early latent syphilis generally occurs within one year of infection. During early 
latency, approximately 25% of untreated patients may experience relapses of 
secondary syphilis as demonstrated by the Oslo study (Gjestland T, 1955).   
 
Late latent syphilis occurs after one year of infection. During this stage, serologic 
testing is positive but sexual transmission is unlikely.  In late latent syphilis, the 
patient harbours the infectious organisms in their spleen and lymph nodes (Radolf JD, 
1991).  Here relapses cease as the patient develops immunity to relapses and 
resistance to reinfection (Ryan KJ, 2004). 
 
Transmission of T. pallidum during latency is possible from relapsing secondary 
lesions and through blood transfusions and mother-to-child transmissions.  Latent 
syphilis ends when the patient has been treated appropriately or when symptoms of 







(2.8.4)  Tertiary Syphilis 
 
Approximately one third of untreated patients develop tertiary stage syphilis some 5 
to 20 years after initial infection (Ryan KJ, 2004).  Tertiary syphilis is a slow 
progressing, inflammatory stage with the potential to affect any tissue or organ in the 
body.   Today with appropriate antibiotic treatment for syphilis, the late 
manifestations of tertiary syphilis are rarely seen.  Tertiary syphilis is subdivided into 
neurosyphilis, cardiovascular syphilis and late benign gummatous syphilis.  
Cardiovascular and gummatous syphilis used to be more prevalent manifestations of 
tertiary syphilis before penicillin became available, however neurosyphilis is currently 
the dominant form of tertiary syphilis.   
 
Neurosyphilis may manifest as meningovascular syphilis, general paresis or tabes 
dorsalis. Meningovascular syphilis involves gummatous and obliterative vascular 
changes of the meninges. This is associated with an increased number of cells and an 
increased protein concentration in the CSF as well as with focal neurologic changes 
(Corey L, 1984).  In general paresis, there is extensive cortical degeneration of the 
brain with vast amounts of treponemes found in affected areas (Corey L, 1984).  
Other changes include reduced memory, hallucinations or psychosis (Corey L, 1984).  
In tabes dorsalis there is “demyelination of the posterior columns and dorsal roots and 
damage to dorsal root ganglia” (Corey L, 1984).  The latter causes “ataxia, wide-
based gait, foot slap and loss of the sensations of position, pain and temperature” 




Cardiovascular syphilis is mainly the result of “local inflammation induced by the 
multiplication of treponemes within the wall of the thoracic aorta” (Radolf JD, 1991).  
The most common manifestation of cardiovascular syphilis is aortitis.  The aortitis 
may be asymptomatic and is “detected on chest radiograph by linear calcification or 
widening of the aorta” (Chiu and Radolf, 1994).  There are three major symptomatic 
forms of cardiovascular syphilis.  These include aortic insufficiency, coronary ostial 
stenosis and aneurysm.  Aortic insufficiency is the result of dilation of the aortic root, 
whilst angina is the most common manifestation of coronary ostial stenosis (Chiu and 
Radolf, 1994).  Aneurysms are associcated with a variety of syndromes including 
“aortic valve incompetence, pressure necrosis of structures adjacent to the aorta or 
rupture of the aorta” thus resulting in sudden death (Corey L, 1984; 
meddean.luc.edu/lumen/Meded/mech/cases/case21/syphilis.htm) 
 
A localized, granulomatous reaction to T. pallidum infection is referred to as a 
gumma.  Gummas are highly destructive and commonly occur in skin, bones and 
joints but can potentially affect any organ.  It manifests similarly to that of other 
mass-producing tissue lesions such as tumours.  Diagnosis of a gumma involves 
serologic evidence of the disease along with its characteristic histologic features 
(Corey L, 1984). 
 
(2.8.5)  Congenital Syphilis 
 
Congenital syphilis refers to the transplacental transmission of T. pallidum from an 
infected mother to her developing fetus.  Symptoms of congenital syphilis are 
analogous to that of secondary syphilis in an adult (Ryan KJ, 2004).  Congenital 
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syphilis may occur at any stage in pregnancy with the risk of transmission to the 
unborn being greater during early maternal syphilis than in the later stages (Sheffield 
et al., 2002).  If infected pregnant women are treated appropriately during their first 
two trimesters of pregnancy, the possibility of negative outcomes will be reduced.  On 
the other hand, late or inadequate treatment could result in spontaneous abortion, fetal 
damage, fetal death, stillbirth or disease in the infant (Ryan KJ, 2004; Lukehart and 
Lafond, 2006).  
 
(2.9)  Treatment for Syphilis 
 
Since its introduction in the late 1940s, till today, pencillin remains the preferred 
antibiotic for treating all stages of syphilis including congenital syphilis (Chiu and 
Radolf, 1994).  In vitro and in vivo animal studies have demonstrated the exquisite 
susceptibility of T. pallidum to this agent.  The bacterium is killed by low levels of 
penicillin G.  A concentration of 0.03 IU/mL (0.018 µg/mL) of penicillin is regarded 
therapeutic (Chiu and Radolf, 1994).  However, the preparations used, the dosage and 
duration of treatment depend on the clinical stage and manifestations of the disease 
(Kinghorn GR, 1999).  No resistance of T. pallidum to penicillin appears to have 
developed.   
 
Health care facilities in developing countries often lack the necessary equipment and 
trained laboratory personnel to make a diagnosis of syphilis on-site.  To overcome 
this, a syndrome-based approach to the management of STIs has been introduced and 
implemented across several developing countries. The syndromic management 
approach is based on the identification of a syndrome i.e. a group of symptoms a 
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patient complains of along with easily recognizable signs upon clinical examination.  
If an STI syndrome is identified combination treatment is provided that covers the 
majority of organisms responsible for that syndrome in a particular geographical area 
(Altini and Coetzee, 2005, Vuylsteke B, 2004).  For example, a patient whom 
clinically presents with a genital ulcer will be treated according to syndromic 
management guidelines for genital ulcers.  This includes treatment for primary 
syphilis. Later stages of syphilis do not present as part of an STI syndrome and are 
therefore not covered by the syndromic management approach. 
 
(2.10)  Laboratory Diagnosis of Syphilis  
 
An accurate diagnosis of syphilis has proven complicated due to the inability to 
culture T. pallidum in vitro or stain it with simple laboratory stains.  Furthermore, 
specimen source from latent and late stages are not available since lesions are absent 
(Karp et al., 2009).  Over the years, scientists, worldwide, have sought for alternative 
laboratory methods to identify syphilitic infection in the various stages of disease. 
Various methods have been established up to date.  Clinical symptoms, the 
identification of T. pallidum in lesion exudate and antibody detection tests form the 
basis for diagnosing syphilis (World Health Organization, 1985).   
 
(2.10.1)  Darkfield Microscopy 
“In many cases, clinical manifestations are highly characteristic” (Radolf JD, 1991).  
If one or more lesions are apparent, then darkfield microscopy can be used to 
visualize viable treponemes within lesion exudate (Radolf JD, 1991).  Since its 
emergence in the 1920s, darkfield microscopy has proven to be the most rapid and 
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direct means of identifying treponemes within exudate obtained from lesions of 
patients with primary, secondary or early congenital syphilitic infection (Chiu and 
Radolf, 1994; Tramont EC, 2005).  It is at these stages of a syphilitic infection that 
treponemes in lesions are in abundance and darkfield examination is most successful.   
T. pallidum subsp pallidum has characteristic morphology and motion that 
distinguishes it from other spiral organisms.  It has a corkscrew appearance and 
moves in a spiralling motion with a 90
o
 undulation about its midpoint (Tramont EC, 
2005).  Prepared slides should be viewed immediately after specimen collection for 
the presence of motile treponemes where the identification of a single treponeme is 
sufficient for diagnosis (Chiu and Radolf, 1994).  The organisms loose motility if 
viewing of the slides is delayed.  T. pallidum subsp pallidum cannot be distinguished 
from the other pathogenic subspecies by means of microscopy (Creighton ET, 1990; 
Larsen et al., 1995). Furthermore, darkfield microscopy is not suitable for examining 
specimens obtained from mucosal surfaces (from oral and anal lesions) due to the 
difficulty in distinguishing T. pallidum from commensal treponemes present in these 
cavities (Chiu and Radolf, 1994).    
 
Preparations should be viewed for at least ten minutes before being considered 
negative (Chiu and Radolf, 1994). Positive identification of treponemes upon 
darkfield examination provides a “specific and immediate diagnosis of syphilis” 
(Larsen et al., 1995).  However, a negative examination does not exclude the 
diagnosis of syphilis.  It is possible that too few organisms are present in the specimen 
to be detected due to the lesion being in the healing stage of infection or the 
treponeme may have altered by systemic or topical disease treatment (Larsen et al., 
1995).  In addition, the presence of numerous erythrocytes, air bubbles or tissue 
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fragments may obscure visualization of treponemes and the darkfield specimen will 
have to be reported as unsatisfactory (Larsen et al., 1995). Furthermore, an 
inexperienced observer can be easily mislead by the presence of artifacts such as 
cotton fibres and Brownian motion (Larsen et al., 1995).  Hence, darkfield 
microscopy requires considerable skill and experience to make an accurate diagnosis. 
It has been reported that the sensitivity of darkfield microscopy approaches 80% 
(Daniels and Ferneyhough, 1977; Larsen et al., 1995). 
 
 
Figure 10:  The presence of treponemes as viewed by darkfield microscopy.   
(CDC guidelines depts.washington.edu/nnpts/online_training/std_handbook) 
 
(2.10.2)  Animal Infectivity Testing 
 
Animal infectivity testing is the oldest and most sensitive method for the detection of 
T. pallidum infection in clinical specimens. It is considered the gold standard for 
determining the sensitivity of other detection methods including PCR (Grimprel et al., 
1991; Sanchez et al., 1993; Lukehart et al., 1988).  Numerous animals from hamsters 
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to chimpanzees were used for maintaining treponemes or to determine infectivity. 
However not all these animals developed noticeable signs of infection or reactive 
serologic tests (Larsen et al., 1995; Wilcox and Guthe, 1966) to procede further.  
Among these, the rabbit proved to be most practical animal for maintaining 
treponemes and to determine its development of infection.  In addition, a syphilitic 
lesion is produced at the site of inoculation in the rabbit.   
 
(2.10.2.1)  Rabbit Infectivity Testing (RIT) 
 
Rabbit infectivity testing (RIT) became the gold standard for detecting T. pallidum 
from clinical specimens, to which other methods are compared.  The sample, either 
CSF or whole blood is inoculated (within 30 minutes of collecion) into rabbits intra-
testicularly and then monitored for the development of orchitis with treponemes 
visible in testicular extract (Chiu and Radolf, 1994).  In rabbits that have not 
developed orchitis yet, serum samples are subjected to serologic testing for syphilis at 
monthly intervals.  If the rabbit fails to seroconvert after 90 days, the RIT is negative.  
Rabbits that seroconvert are sacrificed and its testes extracted and minced.  The 
presence of treponemes in this extract is indicative of a positive RIT (Chiu and 
Radolf, 1994).  If there are no treponemes seen, a second rabbit should be inoculated 
with the testicular extract of the first one (Chiu and Radolf, 1994).   
 
RIT is highly sensitive, and can approach 100% if the number of treponemes exceeds 
23 (Magnuson et al., 1956).  However, RIT is cumbersome, expensive and requires 3 
to 6 months to complete (Larsen et al., 1995; Singh and Romanowski, 1999).  Hence, 
this method proves impractical for routine clinical use.   
36 
 
(2.10.3)  Serologic Tests for the Diagnosis of Syphilis 
 
Serological tests provide a more practical method for diagnosing syphilis and provide 
the only means for identifying asymptomatically infected persons (Radolf JD, 1991).  
Over the years, numerous serological tests have been developed that aim to detect one 
of two different types of antibodies. Therefore two categories of serological tests are 
recognised: nontreponemal tests, that detect antibodies to a combination of 
cardiolipin with cholesterol and lecithin and treponemal tests that detect antibodies 
directed to specific T. pallidum antigens.  Both types of tests should be performed 
when diagnosing syphilis as the treponemal tests serve as the confirmatory tests to 
positive nontreponemal test reactions. 
 
(2.10.3.1)  History of the Development of Serologic Tests for Syphilis 
 
The year 1906 saw a major breakthrough in treponemal research with the 
development of the first serologic test for syphilis called the Wasserman test, an 
adaptation of the complement fixation test that was discovered by Bordet and Gengou 
in 1901 (Wasserman et al., 1906).  Liver extract obtained from newborns whom had 
died from congenital syphilis, was used as the antigen in this test.  The Wassermann 
antigen was initially considered to be specific but it was later revealed that other 
tissues such as beef heart extract could also serve as antigen (Eagle H, 1937; Larsen et 
al., 1995). The addition of cholesterol and lecithin increased the sensitivity of the 
antigens (Eagle H, 1937; Larsen et al., 1995).  The complement fixation tests had 
contributed significantly towards the diagnosis of syphilis, but was accompanied with 
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some drawbacks as well.  The test was difficult to perform, required the use of several 
reagents and a period of 24 hours to complete. 
  
This test was later followed by the precipitation test as developed by Michaelis in 
1907 (Michaelis L, 1907) and Meinicke in 1917 (Meinicke E, 1917).  These tests used 
watery and sodium chloride extracts of syphilitic livers, respectively.  These tests did 
not rely on complement.   
 
Kahn, in 1922, introduced a flocculation test that did not need complement and could 
be viewed within a few hours macroscopically (Kahn RL, 1922).  This test underwent 
several modifications each time improving its sensitivity and specificity.  However, 
this test used crude extract of tissue which varied in quality, hence making 
standardization difficult.   
 
In 1941, Pangborn isolated the active antigenic component from beef heart, a 
phospholipid called cardiolipin (Pangborn MC, 1941).   The combination of 
cardiolipin with lecithin and cholesterol, resulted in the formation of a serologically 
active antigen for detecting syphilis antibodies.   Furthermore, the antigen could be 
standardized both chemically and serologically thus ensuring greater reproducibility 
of test results (Rudolph and Larsen, 1993).   
 
(2.10.3.2)  Nontreponemal Tests 
 
The earliest cardiolipin antigens used to measure syphilis antibodies were crude 
extracts prepared from beef livers or beef hearts, as mentioned earlier.  However this 
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often produced false positive reactions.  Today with the use of the pure preparation of 
the cardiolipin-cholesterol-lecithin complex, fewer false positive reactions are 
obtained (Tramont EC, 2005).  It is believed that these lipids are derived from the host 
and become integrated with the T. pallidum membrane during their interaction in 
infection.  Antibodies directed to this lipid complex are termed, “reagin” (Ryan KJ, 
2004).  But note, that the cardiolipin complex is not exclusive to T. pallidum 
infection.  Reagin antibodies may be produced in response to other treponemal 
diseases as well as nontreponemal diseases resulting in tissue damage (Catterall RD, 
1972; Ryan KJ, 2004).  Hence, due to the non-specific nature of these antibodies, a 
reactive nontreponemal test itself cannot be used to provide a definite diagnosis of    
T. pallidum infection. Further serological evidence is required. 
 
Nontreponemal tests serve two purposes: Firstly, they are the primary screening tests 
for patients with suspected syphilis.  Secondly, serial measurement of nontreponemal 
antibody titres is done to assess disease activity and response to treatment (Chiu and 
Radolf, 1994).  This is because the height of the antibody titre is directly related to 
activity of disease.  Reactivity to nontreponemal tests develops only 1 to 4 weeks 
following the appearance of the primary syphilitic chancre (Morton RS, 2004; 
Kinghorn GR, 1999).  Secondary syphilis is accompanied by the highest titres 
(Morton RS, 2004; Kinghorn GR, 1999). 
 
The most commonly used nontreponemal tests are the Venereal Disease Research 




The VDRL slide test is the standard nontreponemal test, in which heated serum 
(56
o
C) is tested for its ability to flocculate cardiolipin-cholesterol-lecithin antigen 
suspension (Tramont EC, 2005).  This test can be rapidly performed, is reproducible 
and provides acceptable levels of sensitivity and specificity (Harris et al., 1946).  It is 
now most often used to monitor a patient’s response to treatment (Tramont EC, 2005).  
Modifications of the VDRL for routine screening of syphilis include the unheated 
serum reagin (USR) test, the rapid plasma reagin (RPR,18mm-circle) card test, its 
automated version, the automated reagin test (ART), the reagin screen test (RST) and 
the toluidine red unheated syphilis test (TRUST). 
 
In each of these tests, reagin antibody is detected by measuring the flocculation or 
agglutination of the antigen suspension.  In the VDRL and USR tests, antigen-
antibody flocculation is observed with a microscope whilst other tests view 
agglutination macroscopically.  The RPR and TRUST further use charcoal and red 
paint pigment respectively, added to the USR reagent to enhance visualization of the 
antigen-antibody agglutination.  These reactions can therefore be viewed 
macroscopically (Kinghorn GR, 1999; Creighton ET, 1990; Larsen SA, 1990; and 
Larsen et al., 1984).   
 
Of these macroscopic tests, the RPR is most widely used. It has several advantages as 
compared to the VDRL. These are “antigen stability, the ability to use plasma instead 
of serum, and macroscopic observation” (McGrew et al., 1968; Lafond and Lukehart, 
1995).  Nevertheless, the VDRL is still in use within certain laboratories.  The 
sensitivities of the RPR and VDRL vary among the different stages of disease.  The 
tests are negative upon the appearance of the primary chancre, i.e. disease of short 
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duration.  Following several weeks of infection, the tests provide positive readings.  
The reported mean sensitivities of RPR and VDRL during primary syphilis are 86% 
and 78% respectively, whilst the sensitivities of both tests during secondary syphilis 
reaches 100% (Larsen et al., 1995).   
 
Nontreponemal test results are positive early in infection but revert back to normal 
following successful treatment.  Hence, it allows one to monitor the duration of the 
infection and response to treatment thereafter.   
 
In summary, nontreponemal tests are cost-effective, simple and easy to perform and 
sensitive. They can be used to screen large amounts of sera in areas of high 
prevalence as well as to monitor duration of infection and treatment status. 
 
However, since they detect antibodies to the cardiolipin complex they are non-specific 
and may result in false positives due to cross-reacting antibodies in patients with viral 
infections (Epstein–Barr, hepatitis, varicella, measles), leprosy, lymphoma, 
tuberculosis, malaria, endocarditis, connective tissue disease and liver disease. False 
positive results can occassionally occur in pregnant women, HIV infected patients, 
intravenous drug use or contamination (Ryan KJ, 2004; Chiu and Radolph, 1994). 
Hence, if positive, they must be confirmed by one or more specific treponemal tests. 
Also, false negatives may occur with undiluted sera due to an excess of antibody or 
the presence of blocking antibodies, known as the “prozone effect” (Chiu and 





(2.10.3.3)  Treponemal Tests 
 
Treponemal tests are specific to T .pallidum since they detect antibodies directed to  
T. pallidum antigens (Ryan KJ, 2004).  They are used to confirm positive 
nontreponemal test results of presumed syphilitic patients.  The most commonly used 
treponemal tests are haemagglutination tests and immunofluorescence tests.  
 
(a)  T. pallidum Immobilization (TPI) test 
 
The year 1949, saw the development of the first treponemal antibody test, by Nelson 
and Mayer, which they called, the T. pallidum immobilization (TPI) test (Nelson and 
Mayer, 1949).  This test uses testicular tissue extract of rabbits, containing viable      
T. pallidum (Nichols strain) as its antigen.  It “is based on the ability of patient’s 
antibody and complement to immobilize living treponemes, as observed by darkfield 
microscopy” (Larsen et al., 1995).  The TPI test was initially considered the standard 
treponemal test in the United States (Larsen et al, 1984; Larsen et al., 1995) and it 
was specific.  However, the test proved complicated, technically difficult, expensive 
and time-consuming (Larsen et al., 1995).  By the 1970s, the test was found to be 
less-sensitive and specific (Hederstedt B, 1976; Rein et al., 1980) when compared to 
other treponemal tests.  Nevertheless, the TPI test continues to be used in the United 







(b) Fluorescent-Antibody Tests 
 
The fluorescent treponemal antibody (FTA) test, introduced in 1957 was a major 
breakthrough in the quest for developing more efficient treponemal antigen tests 
(Deacon et al., 1957).  This test required that the patient’s serum sample be diluted 
1:5 in saline solution and then reacted with a suspension of killed treponemes that 
were fixed onto a slide.  This was followed with a fluorescein labelled anti-human 
immunoglobulin.  The slides are examined under a microscope with UV light 
whereby fluorescence of the treponemes indicates the presence of anti-treponemal 
antibodies in patients’ sera.  Non-specific reactions were encountered in this FTA test 
due to the occurrence of cross reaction with common antigens shared by both            
T. pallidum and non-pathogenic treponemes that form part of the normal flora in 
humans (Deacon and Hunter, 1962).  Hence, the FTA-test was superceded by the 
more specific and sensitive FTA absorption (FTA-ABS) test whereby the serum 
sample is first diluted in a sorbent made from the nonpathogenic Reiter treponeme, for 
the removal of nonspecific anti-spirochetal antibodies often found in normal serum 
(Hunter et al., 1964; Deacon and Hunter, 1962; Ryan KJ, 2004).   
 
Today, the FTA-ABS and the FTA-ABS double-staining test that requires the use of 
incident illumination microscopes (Hunter et al., 1979) continue to remain standard 
treponemal tests for syphilis (Larsen et al., 1995).  However, since the FTA-ABS 
requires flourescence microscopy, it requires this expensive piece of equipment as 
well as trained personnel.  A further disadvantage to this test is that it is standardized 
at one serum dilution (1:5) and as with most immunofluorescence tests, its 
interpretation can be subjective.  It therefore requires great attention to detail, is 
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difficult to standardize from one laboratory to another and is difficult to quantify 
(Tramont EC, 2005).  Hence, the search for reliable, efficient yet inexpensive 
treponemal tests continued. 
 
(c) Haemagglutination Tests 
 
In 1965, Rathlev reported the first of the haemagglutination techniques to the 
serologic diagnosis of syphilis (Rathlev T, 1965).  In her study, she used formalinized, 
tannine treated sheep erythrocytes that were sensitized with ultra-sonicated Nichols 
strain derived antigen.  If treponemal antibodies are present in the patient’s sera, it 
resulted in agglutination of the sensitized erythrocytes.  
 
Modifications to Rathlev’s method later led to the development of other 
haemagglutination tests such as the microhemaagglutination assay for antibodies to  
T. pallidum (MHA-TP), HATTS and the Treponema pallidum haemagglutination 
assay (TPHA).  These tests also measure the ability of sera to agglutinate erythrocytes 
that were previously sensitized with T. pallidum sonicates.  Sheep erythrocytes are 
used in the MHA-TP test (Tomizawa and Kasamatsu, 1966), turkey erythrocytes in 
the HATTS test (Wentworth et al., 1978) and fowl erythrocytes in the TPHA test 
(ImmuTrep TPHA, Omega Diagnostics).  These tests are performed in a microtitre 
plate.   
 
The FTA-ABS test is still more sensitive, however the haemagglutination tests are 
cheaper and easier to perform and as result, most laboratories continue to perform 
haemagglutination tests for routine work.   
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In summary, treponemal tests are generally more specific and sensitive than the 
nontreponemal tests, with the FTA-ABS test being highly sensitive in all stages of 
syphilis (Jaffe HW, 1984).  The haemagglutination tests are however easier and 
cheaper to perform than the fluorescent-antibody tests and therefore most laboratories 
use these tests routinely.  None of these tests provide information regarding disease 
activity. 
 
Treponemal tests do have some disadvantages. Firstly, they are costly and technically 
more difficult to perform than nontreponemal tests.  Secondly treponemal tests cannot 
distinguish between an active and a past treated infection.  This is because antibodies 
produced in response to specific treponemal antigens persist for years in the 
individual (World Health Organization, SDI, 2006), hence causing test results to 
remain positive for years, if not for life (Ryan KJ, 2004).  Therefore it cannot be used 
to monitor response to treatment.  Thirdly, most treponemal tests take 1-2 hours or 
more to obtain results. Lastly, although specific for syphilis, it has been reported that 
treponemal tests are falsely reactive in approximately 1% of healthy people who have 
no history or clinical findings of syphilis (Goldman and Lantz, 1971).  The inability to 
completely remove antibodies against commensal spirochetes is suggested to be the 
major cause for these falsely reactive treponemal tests (Chiu and Radolf, 1994).   
 
(2.10.4)  Molecular-based Methods for the Diagnosis of Syphilis 
 
 
(2.10.4.1)  Polymerase Chain Reaction (PCR) 
 
 
Up until now, PCR has not yet been standardized for use in the routine clinical 
diagnosis of syphilis.  However, several research groups have designed primer 
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sequences against genes coding for membrane lipoproteins of T. pallidum. These 
genes are conserved in T. pallidum and therefore provide specific PCR targets (Larsen 
et al., 1995). 
 
In 1991, they amplified the 658 bp gene encoding the 47 kDa surface protein, a 
lipoprotein that is genetically dominant in the human immune response to T. pallidum 
infection (Jones et al, 1984).  They performed the test on clinical specimens such as 
“amniotic fluid, neonatal sera and neonatal CSF” (Jones et al., 1984; Larsen et al., 
1995) for diagnosis of congenital syphilis in neonates.  When these results were 
verified with that of RIT, it produced an overall sensitivity of 78% (Grimprel et al., 
1991; Sanchez et al., 1993).  It has been suggested that this lack of sensitivity may be 
attributed to nonspecific inhibitors of the PCR reaction.  Attempts were then made to 
eliminate PCR inhibition encountered in clinical specimens, by investigating 
alternative methods for isolating DNA from clinical samples (Grimprel et al., 1991). 
 
Noordhoek et al reported on the use of their PCR to diagnose neurosyphilis, by 
detecting the presence of treponemes in small volumes of CSF.  They initially 
amplified the gene encoding a 39 kDa membrane protein, then continued with second 
nested PCR primers since the initial primers from this gene showed a lack of 
specificity (Noordhoek et al., 1991). 
 
A further difficulty was encountered analogous to that seen with serodiagnostic 
testing of neurosyphilis.  It could not differentiate between patients with an active or 
past infection.  Patients who were previously infected with T. pallidum and had 
sought treatment still came up positive on PCR.  At present, PCR cannot differentiate 
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between the presence of a small number of viable treponemes and that of dead 
treponemes whose DNA can yet still be amplified (Larsen et al., 1995).   
 
The amplification of other genes used in the detection of T. pallidum in specimens 
include segments of the TmpA (a 42 kDa membrane protein) and the 4 D antigen (an 
oligomeric protein that has multiple forms) (Hay et al., 1990).  However, the PCR had 
not been evaluated against known serologic tests hence “the reported sensitivity could 
not be compared with that of standard clinical methods” (Larsen et al., 1995). 
 
(2.10.4.2)  The Use of Recombinant Antigens in Serologic Tests 
 
More recently, researchers have attempted to clone and express specific T. pallidum 
genes coding for antigens for direct use in serologic tests for syphilis.  These tests are 
mainly in the form of an ELISA or Western blot.  The majority of the cloned antigens 
to date appear to be membrane-associated lipoproteins that are highly antigenic.  The 
lipid component serves as a hapten that increases antigenicity of that protein (Schouls 
LM, 1992).   
 
Prior to recombinancy, two major drawbacks were encountered in the development of 
serologic tests using specific T. pallidum antigens.  The first was the limited number 
of treponemes available following cultivation in rabbits, resulting in insufficient 
quantities of recovered treponemal protein for use in the test (Larsen et al., 1995). 
 
With recombinant DNA technology, large quantities of recombinant treponemal 
proteins can be expressed in E. coli but a major problem encountered here was 
47 
 
purification.  The recombinant proteins had to be purified before use in order to 
eliminate background response due to antibodies directed against E. coli found in 
normal human sera (Larsen et al., 1995).  This however, was costly.  An alternative 
was that the sera be absorbed with E. coli to remove anti-E. coli antibodies before use.  
However, this was not consistently reproducible thus leading to variations in 
background (Larsen et al., 1995).   
 
The second drawback encountered in the development of specific T. pallidum antigen 
tests was cross-reactivity with commensal spirochetes. Cross-reactivity was also 
observed with some “specific treponemal proteins because of reactivity to the lipid 
component of T. pallidum membrane lipoproteins” (Communicable Disease Centre, 
1964).  This problem could be overcome by the use of nonacylated recombinant 
fusion proteins that could eliminate any nonspecific reactivity (Centres for Disease 
Control, 1988; Sanchez et al., 1993).  This may however result in some loss in 
sensitivity as well.   
 
The TmpA membrane lipoprotein was the first antigen to be cloned for use in a 
serologic test for the diagnosis of syphilis (Schouls et al., 1989).  The TmpA gene 
encoding a 42 kDa protein was used in the development of an ELISA for syphilis and 
was shown to be both sensitive and specific (Schouls et al., 1989).  Its sensitivity was 
compared to the TPHA and FTA-ABS serological tests for syphilis, to which the 
results were almost equal (Schouls et al., 1989; Ijesslmuiden et al., 1989).  The 
authors further reported of a significant correlation between the anti-TmpA antibody 
titer and the VDRL titre for sera obtained from treated syphilitic patients.   Based on 
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these findings, the authors suggested that this test could prove significant in 
monitoring treatment status (Schouls et al., 1989; Ijesslmuiden et al., 1989).  
 
Since then, several other recombinant proteins have been cloned and used towards the 
development of ELISA serodiagnostic tests for syphilis.  Among these are the 34 kDa 
membrane protein TmpB (Schouls et al., 1989) and the 35 kDa membrane protein 
TmpC (Schouls et al., 1991) as well as proteins secreted from the cytoplasm (Norris 
et al., 1993; Strugnell et al., 1990).   
 
Extensive research has been done on the 47 kDa penicillin-binding protein, which is 
abundantly produced by T. pallidum (Jones et al., 1984).  This protein is 
immunodominant and does not cross-react with antibodies against commensal 
spirochetes. An ELISA system incorporating this protein has been investigated by 
several laboratories but the product has not been made available to date (Larsen et al., 
1995). 
 
(2.11)  The Use of Serologic Tests for Syphilis in Point-of-Care Situations 
 
As already discussed, there are numerous serologic tests for the diagnosis of syphilis 
currently available on the market. There are still some in the process of being 
developed and others that are under evaluation.  Each of these tests has its own 
advantages and disadvantages as outlined earlier.  Traditionally in the diagnosis of 
syphilis, nontreponemal tests are used for screening of sera of at risk patients and 
these results are confirmed by the more specific treponemal tests.  The confirmatory 
tests, however advantageous, takes several hours to complete and most of these don’t 
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allow single serum testing.  One must also take into consideration the time taken for 
the nontreponemal test to be performed, followed by its confirmatory test and the time 
taken to analyze the results of both tests.  In point-of-care situations such as the STD 
clinics, prenatal clinics or drug treatment centres this would not be feasible.  Firstly, 
the clinics do not have the trained laboratory personnel to perform and interpret the 
necessary confirmatory tests nor the time to perform these, since clinics are usually 
busy environments.  In these situations treatment should begin immediately and not 
be delayed waiting for the results of the confirmatory test to be made available.   
 
This point is especially important in cases where patients are unable to return to the 
clinic in a timely manner eg. in rural areas where clinics are usually far out.  In such 
situations, a diagnosis of primary syphilis is often based on clinical symptoms and 
clinical history upon which treatment is then administered syndromically.  
 
Clinics may send the samples off-site for testing.  But by the time the results are 
received, the patient has already been treated syndromically and has left the clinic.  
On the other hand, the patient may instead be told to return to the clinic once the test 
results are available.  Failure of the patient to do so would result in him/her not 
receiving appropriate treatment and on time, if the test result is positive.  Further 
unfortunate consequences of this would be long term complications in that patient and 
onward transmission to their sexual partners. 
 
There is also the risk of HIV transmission.  It has been reported that syphilis may be a 
predisposing factor for the transmission of HIV.  According to Chiu and Radolf, 
syphilitic chancres disrupt normal epithelium or mucosal barriers, thus providing 
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portals of entry for HIV into the systemic circulation.  Furthermore, the base of a 
syphilitic chancre contains numerous activated lymphocytes and macrophages, the 
cells that are potential targets and reservoirs for HIV (Chiu and Radolf, 1994).   
 
Hence, the use of a rapid point-of-care test for the early detection and treatment of 
syphilis is critical.  Such a test would also prove extremely beneficial in reducing the 
prevalence of congenital syphilis.  The World Health Organization has reported that 
the mortality rate of infants to congenital syphilis is greater than one million infants a 
year worldwide (World Health Organisation, SDI, 2006).  Congenital syphilis can be 
prevented if infected mothers are identified early and treated accordingly. For several 
years, rapid POC tests for the detection of treponemal antibodies have been widely 
used for the screening of pregnant women.     
 
According to the WHO guidelines for syndromic management of STIs, it states that 
antimicrobial regimens should cover 95% of STI cases.  In 2004, Moodley and 
colleagues had established that in KwaZulu-Natal syphilis, chancroid and granuloma 
inguinale together made up just 5% of the etiology (Figure 4).  Other published 
studies investigating the etiology of GUD in South Africa, confirmed the decreasing 
prevalence of these agents.  Considering that these guidelines were to be applied 
towards the management of GUD, would mean the withdrawal of the antimicrobials 
used to treat these less prevalent infections, from the local guidelines.  However, 
South African policy makers are reluctant to withdraw such treatment in fear of a 
rapid re-emergence of the diseases.  This implies that patients currently presenting 
with GUD continue to receive the full treatment regimen for all causes of GUD.  To 
avoid treatment of a large number of patients for infections that they do not have, the 
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development of rapid point-of-care tests for the exclusion of T. pallidum and            
H. ducreyi in ulcers is critical.   
 
In summary, a rapid point-of-care test is one that can be used in all health care 
settings (including resource limited settings) to allow for immediate informed 
treatment choices (World Health Organization, 2006).  Such a test needs to be cost-
effective, simple and easy to perform, not require sophisticated equipment or special 
storage and transport conditions, can be performed on-site without trained laboratory 
personnel and its results need to be available in a matter of minutes and be interpreted 
with ease.   
 
(2.12)  Aim and Motivation for Current Study 
 
In the above context, this study is aimed towards the development of a rapid point-of-
care test to show that patients are rather not infected with syphilis (i.e. an on-site test 
that effectively demonstrates the exclusion of a syphilitic infection when used to 
diagnose individuals presenting with genital ulcers). This requires an antigen 
detection test with a high sensitivity (and preferably also high specificity) which 
allows for definite, reliable negative test results. This will prevent administering of 
“unnecessary” treatment with penicillin for syphilis thus further preventing a painful 
injection, hypersensitivity reactions in patients and the possible development of 
resistance in T. pallidum and other bacterial species.   
 
At the moment, darkfield microscopy provides the only POC diagnosis for primary 
syphilis (Section 2.10.1) and such technique is not available in resource limited 
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settings or general/routine clinic levels.  Also trained laboratory personnel are 
required to perform this technique since great attention to detail is necessary for 
viewing treponemes.  Serologic tests show positive findings only weeks following the 
appearance of the primary syphilitic chancre.  This study aims at the development of a 
rapid test to detect primary syphilis using primary lesion material.   
 
This POC test also aims to be specific to T. pallidum subsp pallidum by using its rare 
outer membrane protein as the target antigen for detection.  In 1995, Blanco and 
colleagues reported their findings of a treponemal outer membrane porin protein, a   
31 kDa protein which they termed “Tromp1” (Blanco et al., 1995).  Other proteins 
belonging to the Tromp family of proteins include the 65- and 28 kDa proteins.  It has 
been suggested that the Tromps play a pivotal role in the pathogenesis of syphilis and 
immunity (Blanco et al., 1995).   
 
The 31 kDa protein was chosen for the purposes of this study because it is 
significantly enriched in the T. pallidum outer membrane preparation as was 
demonstrated by Blanco and colleagues in 1994 (Blanco et al., 1994).  In addition, 
this protein was reported to have “significant amino acid sequence homology to a 
family of streptococcal surface adhesins” (Blanco et al., 1996) thus suggesting a 
similar function of Tromp1, in T. pallidum, and hence its potential role in syphilis 
pathogenesis (Blanco et al., 1996).  In another study conducted in 1990, freeze-
fracture electron microscopy of the T. pallidum outer membrane was used to 
demonstrate IRS-antibody mediated aggregation of Tromp.  This further suggested 
that Tromp1 could be a key surface-exposed target for specific antibody-mediated 
killing or opsonisation (Blanco et al., 1996). 
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For this study, antiserum was to be raised against the 31 kDa Tromp protein and be 
immobilized onto the immunochromatographic test strip for detection of whole 
treponemes.  Hence, whilst other available serologic tests detect treponemal 
antibodies in syphilitic sera, which can result in cross reactivity, this POC test plans to 
use immobilized specific antibody to detect whole treponemes in ulcer secretions.   
 
Isolating the protein from the organism itself would be extremely difficult for several 
reasons.  Firstly, the T. pallidum outer membrane is highly fragile and there is a lack 
of suitable procedures to isolate and purify the outer membrane.  Secondly, the 
amount of recoverable protein will be less and some protein would have been lost 
during the purification procedure.  Thirdly, only a limited number of treponemes are 
obtained following its cultivation in rabbits.  This would mean that several rabbits 
would have to be sacrificed in order to obtain sufficient number of organisms for the 
isolation of the desired, rare protein for study.  To avoid this, it was decided, for this 
study, to use recombinant DNA technology to clone and express the gene encoding 
the 31 kDa Tromp protein.  The recombinant protein would then be used to raise anti-
treponemal antibodies in rabbits.  Specific antibodies would then be immobilized onto 
an immunochromatographic test strip for the detection of whole treponemes in 









CHAPTER 3  
 




(3.1)  Propagation of T. pallidum 
 
Treponema pallidum subsp pallidum (Nichols strain) was maintained by passaging the 
organisms by intra-testicular injection in a New Zealand white male rabbit free of 
treponemal infection, as previously described by Fieldsteel et al (1981) with slight 
alterations.  Ethical approval for use of animals was granted on March 5
th
, 2008, 
under the reference number 028/08/Animal. 
 
On day 1, T. pallidum (Nichols strain) was inoculated intra-testicularly into a rabbit.  
The rabbit was first anaesthetized using a combination of 12 mg xylazine and 6 mg 
ketamine injected intramuscularly.  Following sedation, the scrotal area was prepared 
for inoculation as follows:  The area was depilated and disinfected sequencially with 
2% chlorohexidine in alcohol (Habitane) and povidone iodine (Betadine; Woudine-
Kyron).  Each testis was inoculated with approximately 0.5 mL of 1:5 diluted 
suspension of testicular tissue from a former rabbit containing T. pallidum. On days 4 
and 9 postinfection, the rabbit was inoculated intramuscularly with 4 mg/mL of 
hydrocortisone acetate.  On day 12, at the time of peak orchitis the rabbit was 
euthanized.  The following procedure was followed.  Preparation of the rabbit was 
executed by trained staff at the Biomedical Resource Unit, Westville campus, UKZN.  
The rabbit was anaesthetized with a combination of ketamine and xylazine.  The 
rabbit was then euthanized by injecting pento-sodium barbitone directly into the heart.  
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The testes were removed aseptically. Each testis was placed into a sterile beaker 
containing 10 mL of phosphate buffered saline with 20% fetal calf serum, for 
transport from the animal facility to the laboratory.  
 
(3.1.2)  Harvesting of T. pallidum 
 
After removal of extraneous tissue, the testes were chopped into fine pieces while 
submerged in 10 mL of PBS as described in Section 3.1.  An additional 5 mL of PBS 
containing 20% fetal calf serum was added to the suspension.  The suspension was 
then placed on a shaker for 30 minutes at 37
o
C.  To concentrate the treponemes and 
remove redundant tissue, the suspension was then centrifuged in a clinical centrifuge 
at 845 x g for 10 minutes. The supernatant was aspirated and transferred to sterile   
1.5 mL Eppendorf tubes in 1 mL volumes each. The presence and viability of 
treponemes was confirmed using darkfield microscopy.  
 
(3.2)  Crude DNA Extraction  
 
The treponemal suspension was aliquoted in 1 mL volumes in 1.5 mL Eppendorf 
tubes as described in Section 3.1.2.  Each of these was centrifuged at 46,620 x g for 
30 minutes and the supernatant discarded. The first pellet was reconstituted in 200 L 
ProbeTec lysis buffer (BD ProbeTec , Becton Dickinson). The suspension was 
transferred to the second tube and the pellet in that tube was resuspended in the same 
volume of buffer. This was repeated till all pellets were concentrated into 200 L in a 
single Eppendorf tube.  This suspension was placed in a heating block at 113
o
C for 30 
minutes to aid lysis.  The resulting crude DNA was then further purified.  
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(3.3)  DNA Purification  
 
Ultra-pure DNA was obtained using the DNA Clean and Concentrator-5 kit from 
ZymoResearch (ZymoResearch Corp).  This kit uses the principle of fast-spin column 
chromatography to rapidly yield high-quality, purified DNA.  The procedure followed 
was according to the manufacturer’s instructions: 
 
Two volumes of specially formulated DNA Binding buffer was added to each volume 
of crude DNA preparation (100 µL aliquots) and mixed by vortexing.  The mixture 
was then transferred to the provided Zymo-spin column within a microcentrifuge 
collection tube (provided with the kit) and centrifuged at 9 391 x g for 30 seconds.  
The flow-through fluid was discarded whilst the DNA remained in the column matrix.  
This was followed by adding 200 L of provided Wash buffer to the column and 
centrifugation at 9 391 x g for 30 seconds.  This wash step was repeated once and the 
collection tube discarded.  The column was inserted into a sterile 1.5 mL 
microcentrifuge tube and 30 µL of nuclease-free water (Fermentas/Inqaba) was 
applied directly to the centre of the column matrix without touching the matrix. This 
was followed by centrifugation at 9 391 x g for 30 seconds to elute pure T. pallidum 
DNA.  The concentration and purity of recovered DNA was then determined. 
 
(3.4)  Measurement of DNA Concentration and Purity 
 
Concentration and purity of recovered DNA was determined using the Nanodrop 
2000,  which is based on the principle of spectrophotometry, whereby the amount of 
ultraviolet radiation absorbed by a solution of DNA (or protein) is directly 
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proportional to the amount present in that sample.  Nucleic acid solutions are 
measured at 260 nm whilst proteins are measured at 280 nm.  Pure DNA in solution 
should have an A260/A280 ratio of purity ranging from 1.8 to 2.0.  A ratio that is less 
than 1.8 indicates the presence of contaminants such as proteins and phenols.   These 
samples should be subjected to further purification. 
 
For measuring DNA, the nucleic acid icon was selected.  The instrument was allowed 
a few seconds to initialize and then zeroed.  Spectrophotometers are usually zeroed 
against reagent blanks which contain everything but the compound to be measured.  
For the purpose of this study, the Nanodrop was zeroed against a distilled water blank, 
since the T. pallidum DNA was eluted in water.  A volume of 1.5 µL of distilled water 
was placed onto the Nanodrop applicator and the arm placed down into the water.  
The blank icon was selected and the instrument zeroed.  The arm was lifted and the 
water was wiped off with soft tissue gauze.  Following this, 1.5 µL of sample was 
applied and the measure icon selected.  Absorbance readings at 260 nm and 280 nm 
along with the A260/A280 purity ratio were obtained.  An A260/A230 ratio was also 
obtained indicating any possible chemical contaminants.  Nucleic acid concentration 
measurements were obtained in nanogram per microlitre (ng/µL). The DNA sample 
was stored at -20
o
C until use. 
 
(3.5) Polymerase Chain Reaction (PCR) – Amplification of the tromp1 Porin 
Gene 
 




The PCR master mix was prepared in a room separate from where DNA extraction 
and DNA addition was carried out.  Electrophoresis and analysis of PCR products 
(amplicons) was performed in the separate amplicon laboratory to prevent 
contamination.    In preparation for PCR, the benchtop, pipettes, tip boxes and tube 
racks were swabbed with 10% bleach followed by 70% ethanol.   
 
(3.5.2)  PCR 
 
PCR was used to amplify the gene encoding the 31 kDa Tromp porin protein.   The 
article titled “Recombinant Treponema pallidum rare outer membrane protein 1 
(Tromp1) expressed in Escherichia coli has porin activity and surface antigenic 
exposure” by Blanco and colleagues in 1996, was used as a reference article for the 
amplification of the tromp1 porin gene.   
 
The aim of the PCR was to generate a PCR product lacking the region encoding the 
Tromp1 signal peptide, hence resulting in the expressed protein being secreted rather 
than the membrane bound product.  This ensures that the protein be produced in 
abundance in the soluble fraction thus allowing for easier purification.  The primers 
published by Blanco et al were used to generate PCR products lacking the region 
encoding the signal peptide.  For the purpose of this study, a CACC nucleotide 
overhang was added onto the N-terminal region of the existing forward primer to 
facilitate directional cloning at a later stage (5’-
CACCCGCGGATCCATTCGGTAGCAAGGATGCCGCA-3’).  No changes were 
made to the reverse primer (5’-CCGGAATTCCTAGCGAGCCAACGCAGCAAC-
3’). Both primers were purchased from Roche Diagnostics. The primers were 
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reconstituted according to the manufacturer’s instructions and diluted to a 
concentration of 0.5 µM for the PCR reactions.   
 
These primers were used in a standard mastermix to generate tromp1 PCR products.  
However the initial results showed nonspecific bands.  Therefore PCR optimization 
was performed to determine optimal concentrations of MgCl2 and dNTPs to be used 
in the reaction.   
 
(3.5.3)  Optimization of the Concentration of dNTPs and MgCl2 for PCR 
 
Optimization was performed by varying the concentration of MgCl2 and dNTPs in the 
mastermix.  The concentration of MgCl2 used in PCR reactions varies from 1 mM to   
5 mM, whilst the dNTP concentration should be between 50 µM to 500 µM.  To 
optimize the performance of the PCR, varying concentrations of MgCl2 (Roche 
Diagnostics) and dNTPs (Roche Diagnostics) were used (Table 1), in a mastermix 
containing 5 µl of 10x Taq buffer (100 mM, Roche Diagnostics) with KCl (500 mM, 
Fermentas/Inqaba Biotec), 0.05 µM of each primer (Roche Diagnostics), 0.001% 
gelatin, 0.25 µL of Taq (0.05 U/µL, Roche Diagnostics) and 10 µL of DNA template 
(55.4 ng/µL) in a final volume of 50 µL. Each reaction mixture was prepared 
independently in a 0.2 mL sterile Eppendorf tube (Lasec).  Preparation of the 







dNTPs (µM) MgCl2 (mM) 
 1 2 3 4 5 
A    50 µM 0 0.5 mM 1 mM 1.5 mM 2 mM 
B    100 µM 0 0.5 mM 1 mM 1.5 mM 2 mM 
C    200 µM 0 0.5 mM 1 mM 1.5 mM 2 mM 
D    250 µM 0 0.5 mM 1 mM 1.5 mM 2 mM 
 
Table 1: Concentration of dNTPs and MgCl2 used in PCR optimization  
 
PCR amplification was performed in the GeneAmp PCR System 9700 thermocycler 
(Applied Biosystems). The PCR reaction mix was denatured by heating to 94
o
C for 2 
minutes The following PCR cycling conditions were used for 30 cycles: denaturation 
at 94
o
C for 30 s; followed by annealing at 45
o
C for 30 s and extension at 72
o
C for    
30 s.  A final extension consisted of one cycle at 72
o
C for 10 minutes.  The 
thermocycler was programmed to maintain the amplified PCR products, at 4
o
C, until 
removal.  The amplified products were analysed under a UV trans-illuminator 
following agarose gel electrophoresis.   
 
(3.5.4)   Agarose Gel Electrophoresis 
 
To determine the integrity and yield of the amplified products as well as to establish 
whether these were of the desired size, the products were subjected to electrophoresis 
in an ethidium bromide containing 2% agarose gel (Appendix A-5) in TBE buffer.  
Standard markers of known molecular weight were run alongside the product to 
estimate its molecular weight.   
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To achieve this, 1.4 g of molecular grade agarose (Whitehead Scientific) was weighed 
out into a beaker to which 70 mL of 0.5x TBE buffer (Appendix A-3) was added.  
The solution was warmed in a microwave oven until the agarose was completely 
dissolved. Then, 70 µL of a 0.05% ethidium bromide solution (Appendix A-4) was 
added under gentle swirling.  The mixture was then allowed to cool to approximately 
45
o
C.  Extra caution was taken when handling ethidium bromide as it is known to be a 
potent carcinogen.  Any ethidium bromide wastes and tips were discarded in the 
provided ethidium bromide disposal buckets. 
 
In the meanwhile, the gel cartridge was set up.  The tray and combs were washed and 
then swabbed with 70% ethanol.   Two combs producing 15 wells each were placed 
along the length of the agarose gel to create two rows of wells for the loading of 
samples.  The gel solution was poured into the gel cartridge and allowed to solidify at 
room temperature for about 30 minutes.  Thereafter the combs were removed 
resulting in neatly formed wells.  The gel cartridge was placed into an electrophoresis 
tank filled with 0.5x TBE buffer.   
 
The amplification products were removed from the thermocycler, gently tapped and 
spun down for a few seconds. Then 5 µL of each sample was mixed with 1µL of 
sample loading buffer (Appendix A-6) on a parafilm sheet and these mixtures were 
then loaded into the wells in the agarose gel.  Samples (which are negatively charged) 
were loaded in a manner such that they would run from the negative anode (black) 
towards the positive cathode (red).  DNA molecular weight marker XIV (100 to 1500 
bp ladder) from Roche Diagnostics was used to determine the size of the DNA 
fragments generated by PCR. The lid of the electrophoresis tank was closed and 
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electrophoresis was performed for 60 minutes at 100 V.   Remaining amplified 
products were stored at -20
o
C until further use. 
 
After electrophoresis, the powerpack was switched off and the lid of the tank was 
lifted.  The gel cartridge was removed from the tank and the gel was placed into the 
Gene Genius gel dock (Bio Imaging Systems) to obtain an image.  The GeneSnap 
Software from Syngene was applied to analyze the images.  
 
It was established that a final concentration of 1 mM MgCl2 and 200 µM dNTPs was 
efficient for this PCR reaction as indicated by the brightest and most clearly defined 
band at the desired region. However, nonspecific secondary bands also appeared in 
the lower molecular weight region.    
 
A second PCR was then performed using the optimized mastermix but with 2 µL of 
template DNA instead of 10 µL.  This provided the same results and also prevented 
wastage of template DNA.  However, the nonspecific secondary bands remained 
present.  Therefore, the annealing temperature and primer concentration was 
optimized using the mastermix with optimal MgCl2 and dNTP concentrations.   
 
(3.5.5)  Gradient PCR 
 
Annealing temperature and primer concentration were simultaneously optimized 
using the MiniOpticon Real-Time PCR system from BioRad.  This optimization can 
often be achieved in a single experiment.  Commonly known as Gradient PCR, this 
technique allows the empirical determination of an optimal annealing temperature 
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using the least number of steps.  Other components of the PCR reaction can be 
optimized simultaneously as was done here, by varying the primer concentration 
against an annealing temperature gradient.   
 
Primer solutions containing 0.5 µM, 0.1 µM, 0.05 µM and 0.025 µM were prepared 
for both the forward and reverse primers.  Four sets of mastermixes were prepared as 
per primer dilution with primer concentration being the only changing factor in the 
mastermixes.  The constitution of these different mastermixes in a volume of 24 µL is 
shown in table 2.  Phusion High-Fidelity DNA polymerase (Finnzymes Reagents) was 
used to create blunt ended PCR products to facilitate directional cloning as required 
by the chosen cloning kit. 
 
Reagent Final Concentration Volume per reaction 
(µL) 
(1) Nuclease-free Water - 13.9 
(2) Phusion Buffer 1x 1 
(3) MgCl2 1 mM 1 
(4) dNTPs 200 µM 0.5 
(5) Forward primer 0.05 µM;  0.01 µM; 
0.005 µM or  0.0025 µM 
2.5 
(6) Reverse primer 0.05 µM;  0.01 µM; 
0.005 µM or  0.0025 µM 
2.5 
(7) Gelatin 0.001% 2.5 
(8) Phusion DNA polymerase 0.008 U/µL 0.1 
(9) Template DNA 55.4 ng/µL 1 
Total  25 µL 
 




Volumes of 24 µL of the different mastermixes were added to each well of a 
MiniOpticon plate, resulting in six rows with decreasing primer concentration per 
well.  This was followed by the addition of 1 µL of T .pallidum DNA extract to each 
of the wells.  The plate was tapped gently and spun down for a few seconds.  
 
Using the gradient function of the system, an annealing temperature gradient of 56 to 
71
o
C [56; 59; 61; 65; 68 and 71
o
C] was set to run in decreasing manner as per column 
of primer dilution.  The MiniOpticon system was programmed accordingly using the 
BioRad CFX Manager software. The plate outlay for the gradient PCR is shown in 
table 3. 
 
 P1 - 0.05 µM P2 - 0.01 µM P3 - 0.005 µM P4 - 0.0025µM 
T1 – 71
o
C • • • • 
T2 – 68
o
C • • • • 
T3 – 65
o
C • • • • 
T4 – 61
o
C • • • • 
T5 – 59
o
C • • • • 
T6 – 56
o
C • • • • 
 
Table 3:  Plate outlay for the gradient PCR (P: final primer concentration; T: 
temperature) 
 
The plate was inserted into the detector of the MiniOpticon and its door was closed.   
The instrument was set to amplify for 35 cycles.  Each cycle consisted of a 
denaturation step at 98
o
C for 30 s and 98
o
C for 10 s; annealing temperature gradient 
[56; 59; 61; 65; 68 and 71
o
C] for 30 s; an initial extension at 72
o
C for 30 s; followed 
by a final extension at 72
o
C for 10 min.  The thermocycler was programmed to 
maintain the amplified PCR products, at 4
o
C, until removal. 
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Amplified products were analysed by means of agarose gel electrophoresis as 
described in Section 3.5.4. Upon analysis, bands corresponding with the desired size 
of ~884 base pairs were found in all the lanes where 0.05 µM of each of the primers 
was used.  No bands were identified in the lanes where lower concentrations of 





C where the bands were most defined.   
 
An annealing temperature of 68
o
C was used for the remaining work.  A second PCR 
now using the optimized conditions was carried out to confirm the presence of the 
tromp1 gene. Nuclease-free water was used as a negative control. Upon confirmation 
of the presence of the gene, the amplification product was removed from -20
o
C 
storage and purified using the PureLink PCR Purification Kit from Invitrogen.   
 
 (3.5.6)  Purification of Amplified (tromp1) Product 
 
The PureLink PCR Purification Kit from Invitrogen is designed to rapidly and 
efficiently remove primers, dNTPs, enzymes and salts from PCR products.  The kit 
applies selective binding of dsDNA to its silica-based membrane in the presence of 
chaotropic salts.  All centrifugation steps were carried out in a microcentrifuge.   
 
Four volumes of a high cut-off PureLink Binding buffer with isopropanol, was added 
to one volume of PCR product.  The sample was then added to a provided PureLink 
spin column in a collection tube and centrifuged at 10 000 x g for 1 minute.  The 
flow-through fluid was discarded.  The addition of binding buffer serves to adjust the 
conditions for the binding of dsDNA to the spin column.  The dsDNA binds to the 
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silica-based membrane in the column and impurities are removed by thorough 
washing with provided Wash buffer as follows:  650 µL of Wash buffer with ethanol 
is added to the column which is then centrifuged at 10 000 x g for 1 minute and the 
flow- through fluid discarded.    The column was then centrifuged at maximum speed 
(18 407 x g) for 2-3 minutes to remove any residual wash buffer.  The spin column 
was then placed into a clean 1.7 mL elution tube supplied with the kit and dsDNA 
was finally eluted in water. A 50 µL volume of nuclease-free water 
(Fermentas/Inqaba Biotec) was added to the centre of the spin column with much care 
taken not to touch the membrane.  The column was incubated at room temperature for 
1 minute and then centrifuged at maximum speed (18 407 x g) for 2 minutes.  The 
column was discarded.  The elution tube now contains the purified PCR product 
which was analyzed on agarose gel electrophoresis to confirm its purity.  The product 
was stored at -20
o
C until further use.   
 
(3.6)  Cloning of the tromp1 Amplification Product  
 
The purified amplification products from Section 3.5.6 were cloned into the 
pET100/D-TOPO vector according to the manufacturer’s instructions. This vector is 
included in the Champion pET Directional TOPO Expression Kit purchased from 
Invitrogen.   
 
The Champion pET Directional TOPO Expression Kit from Invitrogen was chosen 
for cloning and expressing of the tromp1 gene.  This kit directionally clones the blunt-
ended amplified DNA into the pET100/D TOPO vector for high-level, T7-regulated 
expression in E. coli.  The amplified DNA is directionally cloned by adding four 
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bases (CACC) to the 5’ end of the existing forward primer. The vector contains a 
complementary GTGG overhang that recognizes the CACC overhang on the PCR 
product. It invades the 5’end of the PCR product, anneals to the added bases and 
stabilizes the PCR product in the correct orientation (Invitrogen user manual, 2006).   
 
(a) pET100/D-TOPO Vector 
 
The amplified tromp1 gene was cloned into the pET100/D-TOPO vector. “The pET 
TOPO vectors are designed to facilitate rapid, directional cloning of blunt-ended PCR 
products for regulated expression in E. coli” (Invitrogen user manual, 2006).   
 
Important Features of the pET100/D-TOPO Vector: 
- The vector contains the ampicillin resistance gene for the selection of 
transformants.  This ampicillin resistance gene encodes the protein β-
lactamase, which is secreted into the medium where it hydrolyzes ampicillin, 
thus inactivating the antibiotic.  
- pET100 vector allows the expression of recombinant protein with an N-
terminal tag containing the Xpress epitope and a 6x-His fusion tag.  This 
allows the production of recombinant fusion proteins that may be easily 
detected and purified. 
- The N-terminal tag also includes an enterokinase (EK) recognition site for 




- A ribosomal binding site (RBS) is situated upstream of the start codon (ATG) 
in the N-terminal tag to ensure optimal spacing for proper translation.   
- It contains the TOPO cloning site for the directional cloning of blunt-ended 
PCR products. 
- The T7 lac promoter allows for the high-level, IPTG-induced expression of 
the recombinant protein in E. coli strains that express T7 RNA polymerase.   
- It contains the lacI open reading frame that encodes the Lac repressor to 
reduce basal transcription of the gene of interest. 
- The lac operator serves as the binding site for the Lac repressor to reduce 
basal transcription of the gene of interest. 
- The T7 transcription termination region permits efficient transcription 
termination. 
- It contains the pBR322 origin of replication for the low-replication and 
maintenance in E. coli. 
 
        (b)  T7 Regulated Expression  
 
“The Champion pET Expression System uses elements from bacteriophage T7 to 
control expression of heterologous genes in E. coli” (Invitrogen user manual, 2006).  
The BL21 (DE3) E. coli strain “carries the DE3 bacteriophage lambda lysogen” 
which further contains a lac construct.  This construct comprises the following: 
- lacI gene which encodes the lac repressor 




- a portion of the lacZ gene.  
The lac construct is inserted into the int gene thus inactivating this gene.  Meanwhile 
the lacI gene encoding the Lac repressor goes on to repress the expression of T7 RNA 
polymerase from the lacUV5 promoter.  The addition of an inducer, isopropylthio-β-
galactoside (IPTG), “allows expression of T7 RNA polymerase from the lacUV5 
promoter” (Invitrogen user manual, 2006).  When sufficient T7 RNA polymerase is 
produced, it binds to the T7 lac promoter on the pET TOPO vector, thus driving the 
expression of the recombinant protein (Invitrogen user manual, 2006). 
 
Previous studies have demonstrated that there is constantly some basal level 
expression “of T7 RNA polymerase from the lacUV5 promoter in the λDE3 
lysogens” even in the absence of the inducer IPTG (Studier and Moffatt, 1986; 
Invitrogen user manual, 2006).  This does not pose a problem as long as the product 
coded for by the gene of interest is not toxic to the E. coli host.  This is because basal 
level expression of a toxic gene product would lead to plasmid instability and cell 
death.  To accommodate for this, the pET vector is designed with a T7 lac promoter 
(as mentioned above) which further contains a lac operator sequence placed 
downstream from the T7 promoter.  “The lac operator serves as the binding site for 
the Lac repressor, encoded by a lacI gene” (Invitrogen user manual, 2006).   The Lac 
repressor binds to the T7 lac promoter via its lac operator sequence thus blocking T7 
RNA polymerase and basal transcription of the gene of interest.   
 
There are cases however, that the gene product of interest is too toxic to BL21 Star 
(DE3) cells that other E. coli host strains are required for the expression studies.  The 
toxicity of the tromp1 gene to certain E. coli host cells was observed by Blanco et al.  
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They reported that the lethality for E. coli transformants harbouring the intact tromp1 
gene is similar to that observed for many recombinant gram negative porin proteins 
expressed in E. coli (Blanco et al., 1995). 
 
The instructions for users of the Champion pET Expression Kit from Invitrogen 
suggest that for known toxic genes, it is best to perform the expression experiment in 
the BL21 Star (DE3) pLysS strain which they also supply.  This strain differs in that 
it contains the pLysS plasmid which produces T7 lysozyme.  “T7 lysozyme binds to 
T7 RNA polymerase and inhibits transcription.  This activity results in reduced basal 
levels of T7 RNA polymerase, leading to reduced basal expression of T7-driven 
heterologous genes.” (Invitrogen user manual, 2006).  Hence, the overall yield of 
recombinant protein obtained from BL21 Star (DE3) cells is greater than the yield 



















(3.6.1)  Evaluation of pET constructs using pDRAW32 1.1.109  
 
pET constructs can be quickly evaluated for expression of the desired target protein 
using pDRAW32 1.1.109.  Figure 2 shows the computer generated pET100/D/tromp1, 



















Figure 2:  Evaluation of the pET100/D/tromp1 using pDRAW32 1.1.109 
 
 
(3.6.2) Ligation of the tromp1 Amplification Product into pET 100/D-TOPO 
Vector 
 
It had been advised in the instruction manual that in order to obtain the highest 
cloning efficiency, a 0.5:1 to 2:1 molar ratio of PCR product:TOPO vector should be 
used.  This is because the efficiency decreases significantly if the ratio of PCR 
product:TOPO vector is <0.1:1 or >5:1. It had also been suggested that for the pET 
TOPO vector, a 1 to 5 ng of a 1 kb PCR product be used in the cloning reaction that 
will result in a suitable number of colonies.  Since the size of the PCR product in this 
study is <1 kb, it was decided that the product be diluted to 5 ng/µL for the cloning 
ligation reaction.  A range of 0.5 to 1 µL of this dilution was used in the reaction.   
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(3.6.2.1)  TOPO Cloning Reaction 
 
The PCR product along with the provided salt solution and water was thawed on ice 
and the cloning reaction was carried out on ice. The vector was removed from -20
o
C 
storage only when ready to use. Two 0.5 mL reaction tubes were labelled according to 
the varying concentrations of product insert being tested. The final ligation reaction 
mix therefore consisted of water, salt solution, DNA insert and vector in a final 
volume of 6 µL (Table 4). 
 
 Reaction 1 Reaction 2 
Water 3.5 µL 3 µL 
Salt solution 1 µL 1 µL 
DNA insert 0.5 µL 1 µL 
Vector 1 µL 1 µL 
Total 6 µL 6 µL 
 
Table 4:  Components of ligation reaction 
 
 
The ligation reaction ingredients were mixed gently and incubated at room 
temperature for 30 minutes.  The One Shot TOP 10 chemically competent E. coli cells 
(Invitrogen) were placed on ice and 3 µL of each cloning/ligation reaction was added 
to one of two vials (50 µL each) of One Shot TOP 10 chemically competent E. coli, 
mixed gently and incubated on ice for 30 minutes. The cells were then heat shocked at 
42
o
C for 30 seconds and immediately transferred back onto ice for a further 2 minutes 
following which 250 µL of SOC medium, at room temperature, (Invitrogen) was 
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added to each vial without mixing.  The tubes were capped tightly, taped onto a clean 
rack and then placed horizontally in a shaking incubator, 230 rpm at 37
o
C for 1 hour.  
Turbidity of the culture after 1 hour incubation indicated growth.  For plating out the 
E. coli cells involved in the transformation reaction, a hockey glass stick was dipped 
into 100% ethanol and flamed, cooled slightly, flamed and cooled once again for 
approximately 40 seconds. Then, using the heat sterilized glass stick, 100 µL and 50 
µL from each transformation mix was spread on prewarmed selective LB agar plates 
(Appendix B-2), containing 100 µg/mL of ampicillin (Capital Lab Supplies) for 
selection (Appendix B-3). The plates were incubated overnight at 37
o
C.  It was 
necessary to plate out two different volumes of transformation mix to ensure that at 
least one plate will have well-spaced colonies for further processing.   
 
After approximately 16 hours of incubation, the plates were removed from the 
incubator and analysed for transformants.  Growth was best observed on the plates 
spread with transformation reaction mix 2, containing 1µL (5 ng/µL) of DNA insert. 
Well-spaced colonies were best observed on the plates inoculated with 50 µL of each 
transformation reaction mix whilst too dense growth occurred on the plates inoculated 
with a 100 µL reaction mix volume.   
 
(3.6.3)  Analysing for Positive Transformants  
 
(3.6.3.1)  Subcultures of TOP10 E. coli Transformants 
 
This cloning kit does not accommodate for typical blue-white screening (in the 
presence of X-gal medium) that is commonly used for confirming the presence of 
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inserts.  Instead a screening PCR was performed to analyze for positive transformants.  
Firstly, spot inoculated subcultures of transformed TOP10 E. coli colonies were 
prepared. This entailed grids being drawn on the surface of the covers of prewarmed 
LB agar plates (containing 100 µg/mL ampicillin) using a black marker and each grid 
was numbered.  Using sterile loops, randomly selected colonies were picked off the 
original LB agar plates and spot inoculated onto the agar within each grid.  This 
therefore provided numbers to each colony that enabled us to identify those that were 
positive according to the results of the screening PCR.  The subculture plates were 
incubated, inverted at 37
o
C overnight for approximately 16 hours.  The next morning, 
transformant colonies were screened for the presence of the tromp1 insert. 
 
(3.6.3.2)  Screening Transformant Colonies for Recombinant DNA 
 
A varying number of randomly selected colonies were picked off the grids of the 
subcultured LB agar plates and suspended in 100 µL of prewarmed LB media 
(Appendix B-1) containing 100 µg/mL of ampicillin.  The tubes were taped to a clean 
rack and incubated horizontally at 37
o
C for 90 minutes with gentle shaking.  In the 
meanwhile the plates were sealed with parafilm and stored in a plastic bag at 4
o
C until 
further use.   
 
For the screening PCR reaction, the same primers used in the previous PCR reaction 
(Section 3.5.2) were used as they hybridise at the ends of the insert.  However, since 
this was just a screening PCR that did not require the use of expensive Phusion 
products, a different cheaper polymerase was used.  Furthermore since there is no 
blue-white screening, it would mean that several colonies will have to be picked for 
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analyzing positive clones and therefore several reactions would have to be conducted. 
Therefore Taq polymerase along with its 10x PCR buffer from Roche Diagnostics 
were used to minimize cost.  The reaction mix was made to a final volume of 20 µL 
as shown in table 5. 
 
Reagent Final Concentration Volume per reaction 
(µL) 
(1) Nuclease-free water - 11.6 
(2) 10x PCR buffer 1x 2 
(3) MgCl2 (25 mM) 1 mM 0.8 
(4) dNTPs (10 mM) 0.2 mM 0.4 
(5) Forward primer (CACC) 0.05 µM 2 
(6) Reverse primer (BE2) 0.05 µM 2 
(7) Taq polymerase 0.05 U/µL 0.2 
(8) Clone – E. coli broth culture - 1 
Total  20 
 
Table 5:  Components of reaction mix for screening PCR 
 
 
Following incubation, 1 µL broth culture of each clone was added to the mastermix 
that had already been prepared and aliquoted at 19 µL volumes into 0.2 mL 
Eppendorf tubes.  The remaining broths were incubated for an additional 4 hours 
before being stored at 4
o
C until further use.   
 
The PCR reaction mix was denatured by heating to 94
o
C for 5 minutes in a Gene Amp 
PCR system 9700 thermocycler.  The following PCR cycling conditions were used for 
35 cycles:  denaturation at 94
o
C for 30 s; followed by annealing at 55
o
C for 30 s and 
an extension at 68
o





for 10 minutes.  The thermocycler was programmed to maintain the amplified PCR 
products, at 4
o
C, until removal. 
 
The amplified products were then analyzed on agarose gel electrophoresis as 
described in Section 3.5.4.  When positive clones were identified, the remaining of the 
cultures were transferred to 3 mL each of prewarmed LB broth media containing    
100 µg/mL of ampicillin and incubated horizontally, overnight at 37
o
C with shaking 
(230 rpm).   
 
The next day, the cultures were removed from the incubator and 150 µL of each 
culture was mixed with 850 µL of autoclaved pure glycerol aliquots and stored at -
80
o
C should the need arise to revive these cultures for future use.  A 1.5 mL culture 
volume was used for the preparation of pure plasmid DNA (minipreps) from these 
recombinant E. coli cultures.   
 
(3.6.3.3)  Isolation of Pure Plasmid DNA 
 
Plasmid DNA was prepared using the PureYield Plasmid Miniprep System from 
Promega.  This system provides a rapid method to purify plasmid DNA using a silica-
membrane column.  The purified plasmid DNA can be used without further 
manipulation for DNA sequencing or other standard molecular biology techniques.  
The method outlined below was used following the manufacturer’s instructions. 
 
In preparation for plasmid DNA isolation, 1.5 mL of bacterial culture was centrifuged 
at maximum speed (18 407 x g) for 1 minute in a microcentrifuge. After discarding of 
the supernatant, the pellet was resuspended in 600 µL of nuclease-free water 
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following which 100 µL of Cell Lysis Buffer (supplied) was added and mixed by 
inverting the tubes six times.  This was followed by adding 350 µL of cold 
Neutralization solution (supplied) and mixed thoroughly by inverting.  The 
suspension was centrifuged at maximum speed (18 407 x g) for 3 minutes in a 
microcentrifuge and the supernatant was transferred to a PureYield Minicolumn 
(supplied) without disturbing the cell debris pellet.  The minicolumn was placed into a 
supplied collection tube and centrifuged at maximum speed (18 407 x g) for 15 
seconds.  Its flow-through fluid was discarded and the minicolumn was placed back 
into the same collection tube.   
 
For the washing process, 200 µL of supplied Endotoxin Removal Wash was added to 
the minicolumn followed by centrifugation at maximum speed (18 407 x g) for 15 
seconds.  Endotoxin Removal Wash aims to remove protein, RNA and endotoxin 
contaminants from purified plasmid DNA.  A 400 µL volume of supplied Column 
Wash Solution was then added to the minicolumn which was centrifuged at maximum 
speed (18 407 x g) for 30 seconds.   
 
Finally, for the elution of plasmid DNA, the minicolumn was transferred to a clean 
1.5 mL microcentrifuge tube and 30 µL of nuclease-water was added directly to the 
centre of minicolumn matrix, without touching the matrix.  The column was allowed 
to stand at room temperature for 1 minute and then centrifuged at maximum speed (18 
407 x g) for 1 second to elute the plasmid DNA.  The minicolumn was discarded and 




The concentration of the plasmid DNA was determined using the Nanodrop 2000 and 
stored at -20
o
C until use.  The DNA was later diluted in preparation for restriction 
digestion.   
 
(3.6.3.4)  Plasmid DNA Restriction Digest  
 
Plasmid DNA was digested with both restriction enzymes, EcoRI and BamHI since 
the primers used for the amplification of the tromp1 gene contains restriction sites for 







Forward primer BamHI (5’end) ggatcc 5’-CACCCGCGGATCCATTCGGTAGCAAGGATGCCGCA-3’    
Reverse primer EcoRI (5’ end)  gaattc 5’-CCGGAATTCCTAGCGAGCCAACGCAGCAAC-3’ 
 
Table 6:  Restriction enzymes used to digest plasmid DNA 
 
 
Digestion was carried out by mixing 100 ng of plasmid DNA, 1 µL each of EcoRI 
(Fermentas/Inqaba Biotec) and BamHI (Fermentas/Inqaba Biotec), 2 µL of 10x Tango 
buffer (Fermentas/Inqaba Biotec), made up to a final volume of 20 µL with nuclease-
free water.  Tango buffer was provided along with the enzymes to simplify buffer 
selection for double digests.  The samples were mixed gently and quickspun for a few 
seconds.  Restriction digest was performed in a Gene Amp PCR system 9700 
thermocylcer at 37
o
C (temperature at which most restriction enzymes function best) 
for 120 minutes.  This was followed by a final incubation at 65
o
C for a further 20 
minutes to inactivate the enzymes.  Digested products were then analysed on agarose 
81 
 
gel electrophoresis (Section 3.5.4) to confirm the presence of the tromp1 gene 
following cloning.   The products were electrophoresed alongside two molecular 
weight markers.  Molecular weight marker XIV (100 to 1500 bp) was used to show 
the tromp1 insert (884 bp) whilst Marker X (0.07 to 12.2 kbp) was used to show the 
vector (5764 bp) and uncut plasmid DNA (6644 bp) of higher molecular weights.   
 
(3.7)  DNA Sequencing 
 
Sequencing was performed to confirm that the tromp1 insert was cloned into the 
correct reading frame of the pET100/D-TOPO expression vector.  The isolated 
plasmid DNA (recombinant DNA) served as the template for the fluorescent-based 
cycle sequencing reaction.  Varying dilutions of template DNA were used in the 
sequencing reaction. Results were only achieved when the DNA was used neat.  
 
After much optimization (Appendix C – Sequencing Optimization), the existing PCR 
primers had to be redesigned for the sequencing reaction as follows: In one set of 
primers, the restriction sites and the CACC nucleotide overhang (forward primer) of 
the PCR primers were removed.  This resulted in a primer set with the following 
nucleotide sequences: 
 
Forward Sequencing primer:  5’-ATTCGGTAGCAAGGATGCCGCA-3’ 
Reverse Sequencing primer:  5’-CTAGCGAGCCAACGCAGCAAC-3’ 
 
 A second set of primers were designed to a sequence internal to the primers on either 




Forward Sequencing primer:  5’-CATGATAGCGGATGCTGTC-3’ 
Reverse Sequencing primer:  5’-AACAACTCGCCTCCAAT-3’ 
 
The new sequencing primers, purchased from Roche Diagnostics, were reconstituted 
according to the manufacturer’s instructions and diluted to 3.2 pmol/µL for the cycle 
sequencing reaction.   
 
(3.7.1)  Cycle Sequencing Reaction 
 
During the cycle sequencing reaction, the DNA fragment to be sequenced is 
denatured and the resulting template is extended by the incorporation of 
deoxynucleotides (dNTPs) by DNA polymerase.  At some stage during the reaction a 
fluorescent-labelled dideoxynucleotide (ddNTP) that lacks a hydroxyl group attached 
to the 3’ carbon gets incorporated into the growing chain thus replacing the normal 
dNTP.  This causes premature halting of DNA synthesis since the lack of the 3’ 
hydroxyl group means that it cannot form a bond with the next nucleotide.  Hence, 
this results in a series of incomplete DNA fragments whose sizes provide information 
concerning the linear sequence of bases in the DNA.   
 
The ABI Prism BigDye Terminator v3.1 cycle sequencing kit provides the required 
reagent components for the sequencing reaction premixed in a single tube of ready 
reaction mix.  These include deoxynucleotide triphosphates, flourescent-labelled 
dideoxynucleotides (dye terminators), AmpliTaq DNA polymerase, FS, rTth 
pyrophosphatase, magnesium chloride and buffer.  These reagents are suitable for 
performing fluorescence-based cycle sequencing reactions on single-stranded or 
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double-stranded DNA templates, PCR fragments and on large templates such as BAC 
clones.  The sequencing enzyme, AmpliTaq DNA polymerase, FS, is a variant of 
Thermus aquaticus DNA polymerase and contains a point mutation in the active site 
resulting in less discrimination against dideoxyribonucleoside triphosphates 
(ddNTPs).  This mutation is one in which “the phenylalanine is substituted by a 
tyrosine at position 667” (Parker et al., 1996).  This mutation allows for improved 
incorporation of chain-terminating ddNTPs as opposed to the wild-type Taq DNA 
polymerase.  This leads to a more even peak intensity pattern (Parker et al., 1996). 
The enzyme also contains a second mutation in the amino terminal domain that 
eliminates the 5’-3’nuclease activity of AmpliTaq DNA polymerase (ABI Prism 
BigDye Terminator v3.1 cycle sequencing kit, user manual).   
 
The mastermix was prepared for both the forward and reverse primers independently 
as shown in table 7. 
 
Reagent Volume (µL) per well Volume (µL) per 96-well plate 
(1)  Nuclease-free water 5.25 504 
(2)  Ready reaction mix 2 192 
(3)  Primer 0.25 24 
 




A volume of 7.5 µL of each mastermix was aliquoted into each well of a MicroAmp 
96-well reaction plate (purchased from ABI).  This was followed by a volume of     
2.5 µL of plasmid DNA (neat) to each well.  The plate was then sealed with an ABI 
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Prism optical adhesive cover and spun down for a few seconds.  The adhesive cover 
was removed and replaced with a rubber mat.  The plate was put onto a Gene Amp 
PCR system 9700 thermocycler. The reaction mix was denatured at 95
o
C for 10 
minutes.  The following cycling conditions were used for 30 cycles: denaturation at 
96
o
C for 10 seconds; followed by annealing at 50
o
C for 5 seconds and extension at 
60
o
C for 4 minutes.  The thermocycler was programmed to maintain the amplified 
PCR products, at 4
o
C, until removal. 
 
(3.7.2)  Sequencing Product Clean-up 
 
After the sequencing reaction, the extension products were subjected to a clean-up to 
remove excess reagents and to precipitate the DNA.   
 
Fresh stocks of sodium acetate and ethanol were prepared prior to the clean-up.  70% 
ethanol was prepared in the morning and kept at refrigerated temperature until use 
since cold ethanol increases the precipitation of DNA.  The sodium acetate/ethanol 
solution was prepared as shown in table 8. 
 
Reagent x1 (µL) x120 (one full plate) µL 
3 M sodium acetate (pH 5.2)  5 600 
100% ethanol 50 6000 
Total 55 6600 
 
Table 8:  Preparation of sodium acetate/ethanol solution 
 
 
A volume of 55 µL of sodium acetate solution was added to each well without 
mixing.  The plate was sealed with an adhesive cover.  The plate was vortexed and 
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centrifuged in a clinical centrifuge at 3000 x g for 20 minutes.  The cover was then 
removed and the plate was gently inverted onto a folded paper towel and centrifuged 
in this position at 150 x g for 5 minutes.  The plate was removed from the centrifuge 
and 150 µL of 70% cold ethanol was immediately added to each well.  This step had 
to be performed quickly because a delay in the addition of ethanol will result in the 
formation of dye blobs on the sequencing data.  The plate was sealed with an adhesive 
cover and centrifuged at 3000 x g for 5 minutes.  Once again, the adhesive cover was 
removed and the plate was gently inverted onto a folded paper towel and centrifuged 
in this position at 150 x g for 1.5 minutes.  The plate was dried at 50
o
C for 5 minutes 
in a thermocycler.  The plate was sealed with an adhesive cover, then wrapped in foil 
and stored at -20
o
C until ready for use.   
 
When ready to sequence, the dried DNA pellets in each well was reconstituted with 
10 µL of formamide, vortexed and then spun down for a few seconds at 150 x g.  The 
DNA was then denatured at 95
o
C for 2 minutes before being put onto the sequencer.   
 
(3.7.3)  Sequencing Analysis 
 
The sequencing data of recombinant clones were analyzed by means of the Geneious 
Pro 5.0.2. software.  The consensus sequence of the recombinant clones was blasted 
against the tromp1 reference sequence (obtained from GenBank under the accession 
number U16363.1) available on NCBI (blast.ncbi.nlm.nih.gov).  This sequence was 




(3.8)  Transformation of the E. coli Expression Host with Recombinant DNA 
 
The BL21 Star (DE3) and BL21 Star (DE3) pLysS E. coli strains were included in the 
Champion pET Directional TOPO Expression Kit, from Invitrogen, for use as hosts 
for expression studies.  Due to the toxicity of the Tromp1 protein (Blanco et al., 1996) 
the BL21 (DE3) pLysS E. coli cells was used as the expression host in this study.  
pLysS confers resistance to chloramphenicol.  Therefore when preparing LB agar 
plates,    34 µg/mL chloramphenicol (Capital Lab Supplies, Appendix B-4) was added 
in addition to 100 µg/mL of ampicillin.  In addition, the BL21 (DE3) E. coli lacking 
pLysS was also transformed to test for growth.  The kit also provided a pET TOPO 
vector containing the lacZ gene (encoding β-galactosidase) for use as a positive 
expression control.  The pET100/D/lacZ positive control plasmid was also used to 
transform host cells. A vial of the BL21 (DE3) pLysS one shot cells was thawed on 
ice for about 5 minutes prior to use.  The plasmid DNA was diluted to 5 ng/µL of 
which 1 µL of this was used to transform the cells. Cells and DNA were mixed by 
gentle tapping. The vials were incubated on ice for 30 minutes and then incubated for 
30 seconds in a water bath at 42
o
C.  The vials were removed from the water bath and 
immediately placed on ice for 2 minutes after which 250 µL of SOC medium (at room 
temperature) was added to each vial without mixing.  The vials were taped onto a 
microcentrifuge rack and placed on its side in a shaking incubator (230 rpm) at 37
o
C 
for 1 hour. 
 
Following incubation, 30 µL and 100 µL of each transformation reaction mix was 
plated out onto two LB agar plates containing 100 µg/mL ampicillin and 34 µg/mL 
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chloramphenicol. The plates were inverted and incubated at 37
o
C overnight for 
approximately 16 hours.   
 
The next day, following colony growth, spot inoculated subcultures for both the 
positive control and the tromp1 transformant colonies were prepared using LB agar 
plates containing 100 µg/mL ampicillin and 34 µg/mL chloramphenicol (Section 
3.6.2.1). The plates were incubated at 37
o
C overnight for approximately 16 hours.  
These plates are referred to as the masterplates. 
 
This was followed with a screening PCR, as described in Section 3.6.3.2 to ensure 
that the insert was still present and maintained in the clones at this stage.   Plasmid 
DNA was then isolated from positive clones (Section 3.6.3.3) and sequenced (Section 
3.7).  Sequencing was performed to confirm the results of the cloning PCR and to 
ensure correct orientation of the insert.  Confirmation of this allowed proceeding with 
the expression study. 
 
(3.9)  Expression Study 
 
(3.9.1)  Expression of Recombinant Tromp1 protein 
 
Single positive transformants, from the masterplates (control and tromp1 
transformants) were picked and cultured in 10 mL of LB media containing 100 µg/mL 
ampicillin and 34 µg/mL of chloramphenicol for selection of E. coli cells containing 
the expression plasmid. The cultures were incubated overnight at 37
o
C with shaking 
(230 rpm).    
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Immediately after this incubation period, the optical density at 600 nm (OD600) of 
each culture was obtained using the Cary MinUV software.  With each OD600 reading, 
a blank containing uninoculated LB media was used.  Readings were done in 
triplicate.  When the expected OD600 of 0.6 to 1.0 was reached (usually after 15 
hours), the cultures were removed from the incubator.  A 1:20 dilution of each culture 
was prepared using fresh LB media containing the appropriate antibiotics.  This 
allowed the cells to quickly return to logarithmic growth (OD600 of 0.05 to 0.1) to 
reach the appropriate cell density.  The cultures were incubated until they reached 
mid-log growth (OD600 = 0.6). 
 
The mid-log cell density for expression of soluble recombinant Tromp1 at OD600 had 
to be optimized.  The expression study was reproduced several times with OD600 
readings of 0.3, 0.4, 0.6 and 0.8. 
 
When the appropriate OD600 was reached, the cultures were induced by adding 
isopropylthio-β-galactoside, IPTG (Invitrogen, Appendix B-5) to a final concentration 
of 0.5 to 1 mM. A range in the concentrations of IPTG was used to optimize the 
correct concentration for the purposes of this expression study.  The cultures were 
split into two 5 mL volumes each and IPTG was added to one of these.  The 
uninduced half served as a control for each induced culture. 
 
(3.9.2)  Pilot Expression Study 
 
Immediately after the addition of IPTG to each culture, 500 µL from the induced and 
uninduced cultures were removed and transferred to clean 1.5 mL Eppendorf tubes.  
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The aliquots were centrifuged at maximum speed in a microcentrifuge for 30 seconds 
and the supernatant was aspirated.  The cell pellets were stored at -20
o
C until use.  
These are the zero time point samples.  Similarly, samples were taken from each 
culture every hour for 7 hours.    
 
(3.10)  Lysis of E. coli cells 
 
The cell pellets were thawed at room temperature, resuspended in 500 µL of cold lysis 
buffer (Appendix D) and incubated on ice for 30 minutes. The bacterial suspensions 
were sonicated on ice 3 times for 20 seconds until the samples were no longer 
viscous.  After each round of sonication the samples were placed on ice for 20 
seconds.  The sonicates were then centrifuged in a microcentrifuge at maximum speed 
for 10 minutes and the supernatant (soluble fraction) was transferred to a sterile 
Eppendorf tube and stored at -20
o
C.  The pellets (insoluble fraction) were also stored 
at -20
o
C.  Both, the supernatant and pellet protein preparations were subjected to 
Sodium dodecyl sulphate – polyacrylamide gel electrophoresis for analysis of its 
protein content.   
 
(3.11)  Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis  
            (SDS-PAGE) 
 




The supernatant and pellet protein preparations were analysed on SDS-PAGE 
according to the procedure by Laemmli (1970).  Both mini and large gels were 
prepared using the SDS-PAGE systems from BioRad.   
 
The glass plates (11 cm x 11 cm) were sandwiched together with 0.35 mm spacers in 
between to create a mould for the gel preparation.  The assembled plates were then 
clamped together and fixed onto a SDS-PAGE preparation stand.  The bottom and 
sides of the plates were sealed with warmed 3% agarose (Appendix E-1).  A 12% 
acrylamide separation gel (Appendix E-14) was prepared by mixing together 6.7 ml 
of sterile deionized water, 8 mL of 30% acrylamide mix, 5 mL of 1.5 M Tris-HCl (pH 
8.8), 0.2 mL of 10% SDS, 20 µl of N’, N’, N’, N’- tetramethylenediamine (TEMED) 
and 0.1 mL of 10% (NH4)2S2O8 in a glass beaker (Appendix E). The solution was 
gently swirled and immediately transferred into the gel slab using a 1 mL pipette.  
Sufficient space was allowed for the addition of a 1 cm stacking gel.  Before the gel 
began to polymerize, its surface was overlaid with 20% ethanol (Appendix E-7).  This 
step aligns the gel and also prevents the diffusion of oxygen into the gel which would 
otherwise inhibit polymerization.  The gel was allowed to polymerize for 45 minutes 
at room temperature.  The solution remaining in the beaker serves as a reference to 
indicate that the separating gel has polymerized.  After polymerization, the ethanol 
overlay was removed with blotting paper. 
 
A 5% stacking gel (Appendix E-14) was prepared by mixing together  6.1 mL of 
sterile deionized water, 1.3 mL of 30% acrylamide mix, 5 mL of 0.5 M Tris-HCl (pH 
6.8), 0.1 mL of 10% SDS, 10 µL of TEMED and 0.05 mL of 10% (NH4)2S2O8 in a 
glass beaker (Appendix E).  The stacking gel solution was poured directly onto the 
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surface of the polymerized separation gel.  A comb was inserted into the stacking gel 
solution, taking care not to trap any air bubbles underneath the teeth of the comb. The 
gel was allowed to polymerize for 30 minutes at room temperature.  After 
polymerization, the comb was carefully removed, creating neatly formed wells for 
sample loading.  The wells were washed with triple distilled water to remove any 
unpolymerized acrylamide.   
 
Two gels could be prepared and electrophoresed simultaneously.  Furthermore, they 
serve to balance one another during the electrophoretic run.  The gel preparations 
were securely mounted onto the electrophoresis apparatus and the electrophoresis tank 
was filled with 10x electrode buffer [0.25 M Tris-HCl (pH 8.3); 1.92 M glycine and 
1% SDS] (Appendix E-8).  
 
(3.11.2)  Sample Preparation for SDS-PAGE 
 
The supernatant and pellet protein preparations from Section 3.10 were brought to 
room temperature.  Equivalent volumes of supernatant and 2x SDS-PAGE sample 
loading buffer (Appendix E-12) were mixed together and heated at 95
o
C for 5 
minutes.  The pellets were reconstituted in 100 µL of 1x SDS-PAGE sample loading 
buffer (Appendix E-13) each, and then heated at 95
o
C for 5 minutes. 
 
A 10 µL volume of supernatant sample and 5 to 7 µL of pellet sample was loaded into 
the wells of the SDS-PAGE gel.  The protein samples were electrophoresed along 
with a standard molecular weight marker.  The ready-to-use PageRuler Unstained 
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Protein Ladder, from Fermentas/Inqaba Biotec, is a mixture of 14 recombinant, highly 
purified proteins with molecular weights ranging from 10 to 200 kDa.   
 
The protein samples were electrophoresed for 4 hours at 100 V for large gels and 2 
hours at 100 V for minigels.  After electrophoresis, the gels were carefully removed 
from the system and then immersed for 1 hour in isopropanol/acetic acid solution 
(Appendix E-9) to fix the polypeptides onto the gel.  The gels were stained with 
Coomassie Brilliant Blue R250 staining solution (Appendix E-10) overnight on a 
rocker at room temperature.  The next day, the gels were destained for 2 hours in 7% 
methanol/5% acetic acid solution (Appendix E-11), with a change in solution at least 
three times.  The gels were stored in triple distilled water, until photographs were 
taken.   
 
(3.12)  Western Blotting  
 
Western blotting was further used to identify and locate the recombinant Tromp1 
fusion protein based on its ability to bind to specific antibodies.  
 
(3.12.1)  Setup of the Mini-Trans Blot Electrophoretic Transfer Cell Apparatus 
 
To achieve equilibration, the gel was immersed in 100% methanol whilst setting up 
the Western blot apparatus.  A large container was filled with ice cold Towbin 
transfer buffer (Appendix F-1).  A gel holder cassette containing black and white 
holder ends were opened and immersed in transfer buffer.  A filter pad was firmly 
placed on the black holder end whilst still being immersed in buffer.  Similarly two 
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sheets of pre-cut filter paper were placed on the filter pad.  A nitrocellulose membrane 
cut to the dimension of the acrylamide gel was placed on the filter paper.  The gel was 
then placed onto the nitrocellulose membrane.  This was followed by two more sheets 
of filter paper and a final closing filter pad.  The gel cassette holder was then closed 
and inserted into the tank filled with Towbin transfer buffer.  A Bio-ice cooling unit 
(kept frozen at -20
o
C) was inserted into the tank to prevent the system from 
overheating during the electrophoretic transfer, otherwise the gel will stick to the 
membrane.  A magnetic stirrer was placed at the bottom of the tank to obtain a 
consistent equilibrium of buffer.  The gel was electrophoresed at 90 V, 400 mA for 3 
hours.  At the end of the run, the system was dismantled.  The gel was stained with 
Coomassie staining solution (Appendix E-10) and destained with 7% acetic acid, 5% 
methanol (Appendix E-11) as performed in Section 3.11.  This was to ensure that all 
protein bands had been successfully transferred onto the nitrocellulose membrane 
blot.  Hence, the gel should be clear when the transfer is complete.  The membrane 
blot was marked with a pencil at its right hand corner to indicate its correct side and 
was handled with a pair of sterile tweezers at all times.  The blot was washed briefly 
with triple distilled water and then stained with Ponceau S solution (Appendix F-2) 
for 1 minute, to stain the protein.  The solution was then drained and the blot was 
rinsed with triple distilled water until its background was reduced and dried for 








(3.12.2)  Immunodetection for the Presence of N-terminal Xpress Fusion Proteins  
 
The membrane blot was blocked for 1 hour in 20 mL 1x PBS containing Tween-20 
and 5% non-fat dry milk (PBSTM, Appendix F-3), at room temperature on a shaker.  
The membrane was then washed three times with 1x PBS containing 0.1% Tween-20 
(PBST, Appendix F-4) at 5 minutes per wash.   
 
Anti-Xpress antibodies (purchased from Invitrogen) directed against recombinant 
proteins containing the N-terminal leader peptide, Xpress epitope (fusion tag), was 
used as the primary antibody.  The Anti-Xpress antibody is a mouse monoclonal IgG 
antibody that recognizes the Xpress epitope sequence, -Asp-Leu-Tyr-Asp-Asp-Asp-
Asp-Lys found in this leader peptide.  The primary antibody was diluted 1:5000 in   
1x PBS containing 0.05% Tween-20 and 5% non-fat dry milk (PBSTM, Appendix F-
3) and incubated for one hour at room temperature on a shaker.  The membrane was 
then washed three times with 1x PBS containing 0.1% Tween-20 (PBST) at 5 minutes 
per wash, as above.   
 
Goat Anti-Mouse polyclonal IgG conjugated to horseradish peroxidase (HRP), from 
AbD Serotec, was used as the secondary antibody.   The antibody was reconstituted 
according to the manufacturer’s instructions.  The reconstituted secondary antibody 
was diluted 1:5000 in 1x PBS containing 0.05% Tween-20 and 5% non-fat dry milk 
(PBSTM, Appendix F-3) and incubated for one hour at room temperature on a shaker.   
 
A 5 mL volume of BM Blue POD precipitating chromogenic substrate (Roche 
Diagnostics) was added to the membrane and incubated in the dark, at room 
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temperature until the appearance of bands.  The membrane was washed with triple 
distilled water and dried between two Whatmann filter papers.  BM Blue POD is a 
chromogenic substrate for the detection of peroxidase.  It produces a permanent dark 
blue band or spot at the peroxidase binding site on the membrane.   
 
(3.13)  Enzyme Linked Immunosorbent Assay (ELISA) 
 
An indirect ELISA was performed to confirm the results of SDS-PAGE and Western 
Blot.  It is possible that the protein may be present, but in far too low a concentration 
to be detected by these two assays mentioned above.  ELISA produces a colour 
change should the protein be present at low concentrations. 
 
The supernatant protein preparations (taken at all time points at every hour during 
expression, following IPTG induction) were used as the antigen for the ELISA.  The 
protein antigen was coated on an ELISA microtitre plate.  The antigen was diluted 1:2 
with 1x Coating buffer (Appendix G-1).  A 100 µL volume of antigen-coating 
solution was added to all wells.  The plate was covered with a lid and placed into a 
sealed humidified container and incubated overnight at room temperature.  The next 
morning, the well contents were decanted to remove any residual antigen-coating 
solution.  The wells were then washed three times with 1x PBST Wash buffer 
(Appendix G-2).  Remaining protein binding sites were blocked by the addition of 
100 µL of Blocking buffer (Appendix G-3) to each well.  The plate was covered with 
a lid and incubated for one hour at room temperature.  After incubation the well 




Anti-Xpress antibodies (Invitrogen) directed against recombinant proteins containing 
the N-terminal leader peptide, Xpress epitope (fusion tag), was used as the primary 
antibody for this ELISA.  The primary antibody was diluted 1:2000, 1:5000 and 
1:10000 with PBS containing 0.01% Tween-20 and 3% non-fat dry milk (Appendix 
G-4).  A 50 µL volume of each dilution was added to appropriate wells and the plate 
was incubated in a sealed, humidified container for one hour at room temperature.   
After incubation the well contents were decanted and washed three times with 1x 
PBST Wash buffer.   
 
Goat Anti-Mouse polyclonal IgG conjugated to horseradish peroxidase (HRP), 
purchased from AbD Serotec, was used as the secondary antibody for this ELISA. 
The reconstituted antibody was diluted 1:15000 with PBS containing 0.01% Tween-
20 and 3% non-fat dry milk (Appendix G-4).  A 50 µL volume of secondary antibody 
was added to each well and the plate was incubated in a sealed, humidified container 
for one hour at room temperature.   After incubation, the well contents were decanted 
and washed three times with 1x PBST Wash buffer.   
 
SIGMAFAST OPD (o-phenylenediamine dihydrochloride) (Sigma-Aldrich) tablets 
were used as substrate for the detection of peroxidase activity in the ELISA.  The 
substrate solution was prepared according to the manufacturer’s instructions.  A     
200 µL volume of substrate solution was added to each well and the plate was 
incubated in the dark at room temperature for 30 minutes or until a colour developed.  
After the incubation period the reaction was stopped by adding 50 µL of 3 M HCl.  
Stopped reactions were then read at 492 nm in a MicroELISA Autoreader.   










(4.1) Propagation of T. pallidum  
 
The rabbit testicular tissue extract showed a high concentration of motile spirochetes 
when viewed by darkfield microscopy (Figure 1) at a magnification of x450.  Just a 
single rabbit was required for this work. This extract was used throughout the study. 
 
 








(4.2) T. pallidum DNA Extraction and Purification 
T. pallidum DNA was obtained by suspending the testicular extract in ProbeTec lysis 
buffer (BD ProbeTec , Becton Dickinson) followed by heating.  The obtained crude 
DNA was purified as described in Section 3.2.  The concentration of recovered DNA 
as determined by spectrophotometry (Nanodrop 2000) was estimated to be 55.4 ng/µL 
with a purity (A260/A280 ratio) of 1.96 (Figure 2).  
 
 
Figure 2:   Results of quantification of purified T. pallidum DNA as determined using 

















(4.3) Optimization of the Concentration of dNTPs and MgCl2 for PCR 
Figures 3 a and b show the results of optimization of the concentration of dNTPs and 




















Figures 3 a and b:  Optimization of the concentration of dNTPs and MgCl2 for the 
amplification of the tromp1 gene 
 
It was established that a final concentration of 1 mM MgCl2 and 200 µM dNTPs (lane 
C3) was efficient for this PCR reaction as indicated by the brightest and most defined 
band at the desired region of ~884 bp.  In addition, lane C3 contained fewer 
nonspecific bands as opposed to C4-5 and B4-5.  DNA molecular weight marker XIV 













(4.4) Primer Concentration/Temperature-Gradient PCR 
Figure 4 a and b shows the result of optimization of primer concentration and 
annealing temperature for the PCR reaction. 
 
 




























Figure 4 a and b.  Agarose gel electrophoresis showing the amplification products 
obtained at different annealing temperatures and different primer concentrations. 
 
Lanes 1-6 shows the tromp1 amplification product (lacking the signal peptide) 





C).  Lanes 7 to 12 show the results obtained over 
the same temperature range with a final primer concentration of 0.01 µM. Lanes 14 to 
19 and lanes 20 to 25 show the results obtained with a final primer concentration of     
0.005 µM and 0.0025 µM respectively.  However, no bands were identified in these 
lanes, indicating that the optimal conditions for the tromp1 PCR was a final primer 
concentration of 0.05 µM for each of the forward and reverse primers and an 
annealing temperature of 56 to 71
o
C. An annealing temperature of 68
o
C was used 
throughout the study.   
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Figure 5 shows the results following the amplification of the tromp1 gene under 







Figure 5:  Amplification of the tromp1 gene using the optimized mastermix and 




















(4.5)  Purification of the tromp1 Amplification Product  
 
Figure 6 shows the electrophoresis results of the amplified tromp1 gene product 
following purification based on the selective binding of double stranded DNA to 
silica-based membrane in the presence of chaotropic salts.  The presence of a single 






Figure 6:  Agarose gel electrophoresis results of purified PCR product (lane 1); 

















(4.6)  Cloning of the tromp1 Amplification Product 
 
 
TOP10 E. coli cells were transformed with pET100/D/tromp1. Figure 7 shows 





Figure 7:  Selective LB agar plate containing ampicillin, showing single colonies of 




















(4.7)  Screening Transformant Colonies for Recombinant DNA 
 
 
A varying number of randomly chosen colonies were screened for the presence of 
tromp1 inserts by PCR. Colonies were picked off from the subcultures on the LB agar 
plates and suspended in 100 µL LB broth followed by incubation at 37
o
C for 90 
minutes. A PCR targeting the tromp1 insert was performed using the mastermix and 
conditions as discussed in Section 3.6.3.2. The results are shown in figure 8. All 
colonies screened contained the tromp1 insert as indicated by the presence of bands of 



















(4.8)  Restriction Digest of Pure Plasmid DNA  
 
 
Figure 9 shows a restriction digest of the pET100/D/tromp1 plasmid DNA using 
BamHI and EcoRI restriction enzymes.  These endonucleases were selected for the 
digest since the primers used for the amplification of the tromp1 gene contain their 
restriction endonuclease sites at the 5’ends.  The forward primer contains the BamHI 
restriction site whilst the reverse primer contains the EcoRI restriction site.  The 






Figure 9:  Agarose gel electrophoresis of plasmid DNA digested with BamHI and 
EcoRI restriction enzymes (Lanes 1 to 4).  Bands of ~6644 bp region represent 
undigested plasmid DNA whilst the bands at ~5764 bp represent the vector only.  M1: 
molecular weight marker XIV; M2: molecular weight marker X (0.07 to 12.2 kbp).  
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(4.9) DNA Sequencing - Optimization 
 
Sequencing was performed to confirm that the tromp1 insert was cloned into the 
correct reading frame of the pET100/D-TOPO expression vector.  The isolated 
plasmid DNA (recombinant DNA) served as the template for the fluorescence-based 
cycle sequencing reaction.  After using varying dilutions of the template DNA for the 
reaction that proved unsuccessful, it was decided that the DNA be used neat for all 
sequencing reactions.   
 
The primers used for the PCR reaction (Section 3.5.2) were initially used for the cycle 
sequencing reaction as well (Table 1).  The primers were diluted to a final 
concentration of 3.2 pmol/µL for the reaction.  However, after several attempts these 
primers failed to produce a sequencing signal for analyses (Appendix C).   
 
Initial PCR primer set 
Forward primer  5’-CACCCGCGGATCCATTCGGTAGCAAGGATGCCGCA-3’ 
Reverse primer  5’-CCGGAATTCCTAGCGAGCCAACGCAGCAAC-3’ 
 














It was then decided that the PCR primers would be redesigned for use in the 
sequencing reaction in an attempt to decrease the high GC content of both primers and 
shorten their overall length (Table 2). In one set of primers, the restriction sites and 
the CACC nucleotide overhang (forward primer) of the PCR primers were removed.  
A second set of primers was designed to a sequence internal to the primers on either 
end of the insert.  This resulted in primer sets with the following nucleotide 
sequences: 
 
Primer set 1 
Forward primer 1 5’-ATTCGGTAGCAAGGATGCCGCA-3’ 
Reverse primer 1 5’-CTAGCGAGCCAACGCAGCAAC-3’ 
Primer set 2 
Forward primer 2 5’-CATGATAGCGGATGCTGTC-3’ 
Reverse primer 2 5’-AACAACTCGCCTCCAAT-3’ 
 




The new sequencing primers were reconstituted according to the manufacturer’s 
instructions and diluted to a final concentration of 3.2 pmol/µL.  Both newly designed 
primer sets successfully produced sequencing data and were used for all sequencing 






(4.10)  DNA Sequencing of Inserts Following Transformation of E. coli TOP10 
Cells with pET100/D/tromp1 
 
Figure 4.10 shows the DNA sequence of the tromp1 gene as inserted into the 
pET100/D-TOPO expression vector, i.e. the plasmid DNA obtained from a positive 
clone.  This sequence was compared to the tromp1 reference sequence (Figure 4.11) 




























Figure 10:  DNA sequence of the tromp1 gene inserted into the pET100/D-TOPO 
expression vector.  Highlighted in black bold print is the entire tromp1 DNA sequence 
lacking the signal peptide.  Shown in red, is the expression vector with the underlined 
regions indicating the N-terminal polyhistidine and Xpress fusion tags respectively.  
The forward and reverse primers are highlighted in blue.   
 
The tromp1 amino acid sequence begins with a 40-residue hydrophobic region 
presumed to be the signal peptide (Blanco et al., 1995).  However since the signal 
peptide was not required for this study and had been deliberately excluded so as to 
express non-exported, soluble protein, the sequence (Figure 10) lacks a start codon 
(atg).  Instead it uses the start codon on the expression vector, located downstream 
from its ribosomal binding site.  The T7 promoter/priming site is situated upstream 
from the ribosomal binding site.  The stop codon of the tromp1 gene occurs within the 
reverse primer. This sequence showed 100% homology when blasted against the 
tromp1 reference sequence (Figure 11) obtained from GenBank 


















Figure 11:  tromp1 reference gene sequence obtained from GenBank 



















(4.11) Multiple Sequence Alignment   
 
A nucleotide blast between the cloned tromp1 gene and its reference sequence 
(accession number U16363.1) was performed on NCBI (blast.ncbi.nlm.nih.gov).  
Figures 4.12 a and b show the nucleotide blast and multiple sequence alignment of the 
cloned tromp1 gene sequence against its reference sequence, respectively. This shows 





Figure 12 a: Results of a nucleotide blast of the cloned tromp1 insert against the 
nucleotide collection available on NCBI (blast.ncbi.nlm.nih.gov).  The results show 




gb|U16363.1|TPU16363  Treponema pallidum rare outer membrane porin Tromp1 (tromp1)  
gene, complete cds 
Length=1014 
 
 Score = 1594 bits (863),  Expect = 0.0 
 Identities = 863/863 (100%), Gaps = 0/863 (0%) 
 Strand=Plus/Plus 
 
Query  13   CATTCGGTAGCAAGGATGCCGCAGCGGACGGGAAACCCCTGGTTGTCACCACCATTGGCA 72 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95   CATTCGGTAGCAAGGATGCCGCAGCGGACGGGAAACCCCTGGTTGTCACCACCATTGGCA 154 
 
Query  73   TGATAGCGGATGCTGTCAAAAACATCGCTCAAGGTGATGTGCATCTAAAGGGGTTGATGG  132 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  155  TGATAGCGGATGCTGTCAAAAACATCGCTCAAGGTGATGTGCATCTAAAGGGGTTGATGG  214 
 
Query  133  GTCCTGGTGTTGACCCGCACCTGTACACGGCTACTGCGGGGGATGTGGAATGGCTCGGGA  192 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  215  GTCCTGGTGTTGACCCGCACCTGTACACGGCTACTGCGGGGGATGTGGAATGGCTCGGGA  274 
 
Query  193  ATGCGGATCTCATCCTGTACAACGGGTTGCACCTGGAAACCAAGATGGGCGAGGTGTTTT  252 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  275  ATGCGGATCTCATCCTGTACAACGGGTTGCACCTGGAAACCAAGATGGGCGAGGTGTTTT  334 
 
Query  253  CCAAACTGCGCGGGAGCCGCTTGGTAGTTGCAGTTTCTGAGACTATTCCGGTGTCTCAGC  312 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335  CCAAACTGCGCGGGAGCCGCTTGGTAGTTGCAGTTTCTGAGACTATTCCGGTGTCTCAGC  394 
 
Query  313  GTCTTTCTCTTGAGGAAGCAGAGTTCGATCCGCATGTGTGGTTTGATGTAAAGCTGTGGT  372 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  395  GTCTTTCTCTTGAGGAAGCAGAGTTCGATCCGCATGTGTGGTTTGATGTAAAGCTGTGGT  454 
 
Query  373  CTTATTCGGTGAAGGCAGTGTACGAAAGCTTGTGCAAGCTGTTGCCGGGAAAAACTCGCG  432 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  455  CTTATTCGGTGAAGGCAGTGTACGAAAGCTTGTGCAAGCTGTTGCCGGGAAAAACTCGCG  514 
 
Query  433  AATTTACTCAACGTTATCAGGCGTACCAGCAGCAGTTGGATAAGCTTGACGCGTACGTTC  492 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  515  AATTTACTCAACGTTATCAGGCGTACCAGCAGCAGTTGGATAAGCTTGACGCGTACGTTC  574 
 
Query  493  GGCGCAAGGCGCAGTCGCTGCCTGCTGAAAGGCGTGTGTTGGTGACCGCTCATGATGCGT  552 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  575  GGCGCAAGGCGCAGTCGCTGCCTGCTGAAAGGCGTGTGTTGGTGACCGCTCATGATGCGT  634 
 
Query  553  TCGGCTATTTTAGCCGTGCGTATGGTTTTGAGGTGAAGGGGTTGCAAGGGGTGAGCACCG  612 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  635  TCGGCTATTTTAGCCGTGCGTATGGTTTTGAGGTGAAGGGGTTGCAAGGGGTGAGCACCG  694 
 
Query  613  CTTCGGAAGCCAGTGCGCATGATATGCAGGAACTGGCAGCGTTTATTGCGCAGCGTAAAC  672 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  695  CTTCGGAAGCCAGTGCGCATGATATGCAGGAACTGGCAGCGTTTATTGCGCAGCGTAAAC  754 
 
Query  673  TCCCTGCTATCTTTATTGAGAGTTCTATTCCGCACAAAAACGTTGAAGCGTTAAGGGATG  732 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755  TCCCTGCTATCTTTATTGAGAGTTCTATTCCGCACAAAAACGTTGAAGCGTTAAGGGATG  814 
 
Query  733  CGGTGCAGGCAAGAGGGCACGTAGTGCAGATTGGAGGCGAGTTGTTTTCTGATGCGATGG  792 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  815  CGGTGCAGGCAAGAGGGCACGTAGTGCAGATTGGAGGCGAGTTGTTTTCTGATGCGATGG  874 
 
Query  793  GGGATGCGGGTACGAGCGAGGGTACCTACGTAGGGATGGTAACACACAATATCGATACGA  852 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  875  GGGATGCGGGTACGAGCGAGGGTACCTACGTAGGGATGGTAACACACAATATCGATACGA  934 
 
Query  853  TCGTTGCTGCGTTGGCTCGCTAG  875 
            ||||||||||||||||||||||| 




Figure 12 b:  Multiple sequence alignment (blast.ncbi.nlm.nih.gov) of the cloned 
tromp1 insert against the reference sequence 
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(4.12) Transformation of BL21 (DE3) pLysS E. coli cells with pET100/D/tromp1 
Figure 13 shows single colonies following overnight growth of BL21 (DE3) pLysS  
E. coli cells transformed with pET100/D/tromp1 (plasmid DNA), in preparation for 
the expression study.  The transformed E. coli cells were spread on an LB agar plate 






Figure 13:  Selective LB agar plate containing ampicillin and chloramphenicol, 










Figure 14 shows single colonies following overnight growth of BL21 (DE3) pLysS   
E. coli cells transformed with pET100/D/lacZ, which serves as a positive control in 
the expression study.  The control vector contains the lacZ gene (encoding for β-






Figure 14:  Selective LB agar plate containing ampicillin and choramphenicol, 
showing single colonies of BL21 (DE3) pLysS E. coli cells transformed with 
















(4.13) Subcultures of BL21 (DE3) pLysS E. coli Transformants 
 
 
Figures 15 and 16 show spot inoculated subcultures of the pET100/D/tromp1 and 
pET100/D/lacZ transformed E. coli colonies.  This method provides a clone of 





























Figure 16:  Subcultures of BL21 (DE3) pLysS E. coli cells transformed with 





























(4.14) Screening Transformant Colonies for Recombinant DNA 
 
Figure 17 shows the results of the PCR reaction on progeny of individual BL21 (DE3) 
pLysS E. coli colonies transformed with pET100/D/tromp1.  These results show that 
the tromp1 insert is present at this stage and has been successfully transformed into 
the E. coli expression host.    
 
 
                     
Figure 17:  Agarose gel electrophoresis results showing the 884 bp amplification 
products (lanes 1 to 6) for the selection of recombinant clones.  Lane 7 shows the 

















(4.15) DNA Sequencing of the tromp1 Insert Isolated from Transformed BL21 
(DE3) pLysS E. coli  
 
Figure 18 shows the DNA sequence of the tromp1 insert following isolation of the 













Figure 18:  DNA sequence of the overlapping region of the tromp1 insert isolated 
from the transformed BL21 (DE3) pLysS E. coli host, against the tromp1 reference 
























(4.16) Multiple Sequence Alignment 
 
A nucleotide blast of the cloned tromp1 insert and its reference sequence (accession 
number U16363.1) was performed on NCBI (blast.ncbi.nlm.nih.gov).  Figures 19 a 
and b shows the results of a nucleotide blast and multiple sequence alignment of the 
cloned tromp1 insert against its reference sequence, respectively. This nucleotide blast 
shows a 100% homology between the two sequences.   
 
Figure 19 a:  Nucleotide blast of the cloned tromp1 insert against the nucleotide 
collection available on NCBI (blast.ncbi.nlm.nih.gov).  The results show 100% 






gb|U16363.1|TPU16363  Treponema pallidum rare outer membrane porin Tromp1 (tromp1)  
gene, complete cds 
Length=1014 
 
 Score = 1242 bits (672),  Expect = 0.0 
 Identities = 672/672 (100%), Gaps = 0/672 (0%) 
 Strand=Plus/Plus 
 
Query  1    AAAAACATCGCTCAAGGTGATGTGCATCTAAAGGGGTTGATGGGTCCTGGTGTTGACCCG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  172  AAAAACATCGCTCAAGGTGATGTGCATCTAAAGGGGTTGATGGGTCCTGGTGTTGACCCG  231 
 
Query  61   CACCTGTACACGGCTACTGCGGGGGATGTGGAATGGCTCGGGAATGCGGATCTCATCCTG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  232  CACCTGTACACGGCTACTGCGGGGGATGTGGAATGGCTCGGGAATGCGGATCTCATCCTG  291 
 
Query  121  TACAACGGGTTGCACCTGGAAACCAAGATGGGCGAGGTGTTTTCCAAACTGCGCGGGAGC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  292  TACAACGGGTTGCACCTGGAAACCAAGATGGGCGAGGTGTTTTCCAAACTGCGCGGGAGC  351 
 
Query  181  CGCTTGGTAGTTGCAGTTTCTGAGACTATTCCGGTGTCTCAGCGTCTTTCTCTTGAGGAA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  352  CGCTTGGTAGTTGCAGTTTCTGAGACTATTCCGGTGTCTCAGCGTCTTTCTCTTGAGGAA  411 
 
Query  241  GCAGAGTTCGATCCGCATGTGTGGTTTGATGTAAAGCTGTGGTCTTATTCGGTGAAGGCA  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  412  GCAGAGTTCGATCCGCATGTGTGGTTTGATGTAAAGCTGTGGTCTTATTCGGTGAAGGCA  471 
 
Query  301  GTGTACGAAAGCTTGTGCAAGCTGTTGCCGGGAAAAACTCGCGAATTTACTCAACGTTAT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  472  GTGTACGAAAGCTTGTGCAAGCTGTTGCCGGGAAAAACTCGCGAATTTACTCAACGTTAT  531 
 
Query  361  CAGGCGTACCAGCAGCAGTTGGATAAGCTTGACGCGTACGTTCGGCGCAAGGCGCAGTCG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  532  CAGGCGTACCAGCAGCAGTTGGATAAGCTTGACGCGTACGTTCGGCGCAAGGCGCAGTCG  591 
 
Query  421  CTGCCTGCTGAAAGGCGTGTGTTGGTGACCGCTCATGATGCGTTCGGCTATTTTAGCCGT  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  592  CTGCCTGCTGAAAGGCGTGTGTTGGTGACCGCTCATGATGCGTTCGGCTATTTTAGCCGT  651 
 
Query  481  GCGTATGGTTTTGAGGTGAAGGGGTTGCAAGGGGTGAGCACCGCTTCGGAAGCCAGTGCG  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  652  GCGTATGGTTTTGAGGTGAAGGGGTTGCAAGGGGTGAGCACCGCTTCGGAAGCCAGTGCG  711 
 
Query  541  CATGATATGCAGGAACTGGCAGCGTTTATTGCGCAGCGTAAACTCCCTGCTATCTTTATT  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  712  CATGATATGCAGGAACTGGCAGCGTTTATTGCGCAGCGTAAACTCCCTGCTATCTTTATT  771 
 
Query  601  GAGAGTTCTATTCCGCACAAAAACGTTGAAGCGTTAAGGGATGCGGTGCAGGCAAGAGGG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  772  GAGAGTTCTATTCCGCACAAAAACGTTGAAGCGTTAAGGGATGCGGTGCAGGCAAGAGGG  831 
 
Query  661  CACGTAGTGCAG  672 
            |||||||||||| 
Sbjct  832  CACGTAGTGCAG  843 
 
 
Figure 19 b: Multiple sequence alignment (blast.ncbi.nlm.nih.gov) of the cloned 
tromp1 insert against the tromp1 reference sequence, following transformation of 






(4.17)  Gene Expression  
 
Gene expression is studied in the log phase of the E. coli growth curve. This is 
determined by measuring increasing turbidity in a spectrophotometer at OD600. The   
E. coli cultures were incubated until their growth reached OD600 readings of 0.3, 0.4, 
0.6 and 0.8. These values were chosen based on recommendations for mid-log growth 
in the Invitrogen user manual (2006) and publications in the literature (Blanco et al., 
1996).  SDS-PAGE analysis was applied for detection of the gene product, viz 
Tromp1 protein. 
 
Figures 20, 21 and 22 show the SDS-PAGE analysis of the supernatant and pellet 
protein preparations obtained following lysis of the E. coli cells.  This was done at 
different time intervals, following induction with IPTG.  In addition, induced E. coli 
lysates were analyzed against their corresponding uninduced lysates for observation 














Figure 20:  Coomassie blue – stained SDS-PAGE gel analysis of protein supernatant  
samples obtained after 4 hours of IPTG induction 
 
 
Figure 21:  Coomassie blue – stained SDS-PAGE gel analysis of protein supernatant  




Figure 22: Coomassie blue – stained SDS-PAGE gel analysis of protein pellet 




Lanes:   
 
1.  Sample 2 induced with IPTG to a final concentration of 0.5 mM 
2.  Sample 2 induced with IPTG to a final concentration of 1 mM 
3.  Uninduced sample 2  
4.  Sample 3 induced with IPTG to a final concentration of 1 mM 
5.  Uninduced sample 2  
6.  Sample 4 induced with IPTG to a final concentration of 1 mM 
7.  Uninduced sample 4  
8.  Positive expression control induced with IPTG to a final concentration of 
1 mM 
9.  Uninduced positive expression control 
10.  PageRuler protein molecular mass marker (10 to 200 kDa) 
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Protein preparations obtained at various time points at one hour intervals following 
IPTG induction, were analysed by SDS-PAGE and stained with Coomassie blue 
staining solution.  Each induced E. coli lysate was run along its corresponding 
uninduced lysate which served as a negative control.  The recombinant protein is 
visible as a band of increasing intensity over time in the expected size range. 
 
 
However, SDS-PAGE gel analysis showed no difference in the banding pattern 
between the IPTG induced and uninduced lysates, for both the supernatant (Figures 
20 and 21) and pellet protein preparations (Figure 22).  Furthermore, no difference 
was noted between lysates that were induced with IPTG to final concentrations of   
0.5 mM and 1 mM.   
 
The positive control however, shows a bright and distinct band at its expected size 
range of ~121 kDa.  This confirms that growth and induction were properly 
performed.  The recombinant protein of interest is 31 kDa.  However, the addition of 
the N-terminal fusion tag increases the size of the recombinant protein by 3 kDa.  One 
should also account for the additional amino acids between the fusion tag and the start 
of the protein. Five vector-encoded amino acids are present at the N-terminus of this 
recombinant protein. Therefore, the product to look for has a molecular weight of 34 













(4.18) Western Blot Analysis 
 
A Western blot analysis was performed following SDS-PAGE.  Western Blot takes 
SDS-PAGE analysis further in that it detects the protein of interest from within a 
mixture of proteins based on its ability to bind specific antibodies.  In this study anti-
Xpress antibodies specific to the N-terminal Xpress epitope fusion tag were used to 
detect the recombinant protein.   
 
One should expect to see a permanent dark blue band or spot at the peroxidase 
binding site on the nitrocellulose membrane indicating specific antigen-antibody 
binding and hence the presence of the recombinant protein.  However no band was 






























(4.19) Enzyme Linked Immunosorbent Assay (ELISA) 
 
→  Increasing Primary Antibody dilution 
 1 2 3 4 5 6 7 8 9 
A 0.088 0.092 0.094 0.096 0.084 0.091 0.093 0.082 0.089 
B 0.094 0.099 0.099 0.097 0.094 0.094 0.096 0.091 0.092 
C 0.096 0.100 0.097 0.097 0.098 0.094 0.095 0.091 0.096 
D 0.104 0.093 0.096 0.099 0.098 0.097 0.096 0.073 0.099 
E 0.095 0.097 0.095 0.099 0.093 0.095 0.095 0.103 0.099 
F 0.093 0.095 0.097 0.097 0.093 0.093 0.095 0.095 0.095 
G 0.094 0.096 0.101 0.096 0.095 0.094 0.092 0.092 0.092 
H 0.095 0.096 0.098 0.095 0.099 0.090 0.096 0.094 0.095 
 
Table 3:  ELISA using anti-Xpress antibodies to demonstrate any possible levels of 
detectable protein in lysed E. coli cell supernatant extract 
KEY: 
Well number Primary Antibody 
dilution 
 1-3 1:2000 
4-6 1:5000 
7-9 1:10 000 
 




A 0 hour 
B 1 hour 
C 2 hours 
D 3 hours 
E 4 hours 
F 5 hours 
G 6 hours 





















An indirect ELISA was performed to confirm the results of SDS-PAGE and Western 
Blot. As with Western Blot, ELISA too uses specific antibody to detect the 
recombinant protein of interest.   
 
Rows A to H contain the samples obtained at one hour intervals following IPTG 
induction during the 7 hour expression study.  Row A contains the zero time point 
samples from the moment of induction and thereafter the samples are arranged 
according to increasing hours of incubation following IPTG induction. 
 
Theoretically, protein expression should occur in increasing amounts from time point 
0 onwards until it reaches a peak.  This should be followed by a temporary plateau 
phase.  Finally a downward trend in protein expression is expected to follow.  
However the results in Table 3 show no such pattern in protein expression.  
Furthermore the values obtained are far too low to indicate the presence of even a 
little amount of protein.  This therefore confirms the results established from SDS-
PAGE and Western Blot, suggesting the absence of the production of the recombinant 






















The aetiology of genital ulcer disease in South Africa has changed over time from 
predominantly primary syphilis and chancroid to genital herpes and 
lymphogranuloma venereum. Despite this, the guidelines for syndromic management 
of GUD still include penicillin for primary syphilis. The aim of this project was to 
develop a rapid point-of-care test for the exclusion of primary syphilis. This would 
prevent administering of unnecessary treatment for syphilis, preventing a painful 
injection, hypersensitivity reactions in patients and the possible development of 
resistance in T. pallidum and other bacterial species.   
 
This test would be an immunochromatographic (IC) test strip incorporating specific 
antibodies raised against the 31 kDa T. pallidum rare outer membrane porin protein 
(Tromp1), in its test region on the test strip.  The 31 kDa protein was the first            
T. pallidum membrane-spanning outer membrane protein identified (Blanco et al., 
1994).  The protein was chosen for this study due to its high concentration in the       
T. pallidum outer membrane and the uniqueness of this protein to T. pallidum subsp 
pallidum.    
 
 
To be able to produce the required capture antibodies, an amount of soluble Tromp1 
protein was needed. In order to obtain reasonable quantities of pure Tromp1 in soluble 
form, the protein was to be cloned and expressed in E. coli cells as a fusion protein, 
lacking its signal peptide and purified.  
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PCR conditions for the amplification of the tromp1 gene were optimized until a single 
distinct band at the desired region of 884 bp was obtained. Following cloning and 
ligation of amplified tromp1 in the pET100/D-TOPO vector, transformants were 
screened for the presence of inserts by performance of a PCR.  Random colonies 
selected for the PCR all contained the tromp1 insert, indicative of “positive clones”.  
These results were further confirmed by DNA sequencing and digestion of plasmid 
DNA by means of restriction enzymes.  Similar steps were carried out to ensure that 
the tromp1 insert was still maintained following transformation of the BL21 (DE3) 
pLysS E. coli host cells to be used for expression of the gene.  Confirmation of this 
allowed continuation of the experiments to attempt T7-regulated expression of soluble 
Tromp1 protein.  
 
Despite variation in incubation time and IPTG expression inducer concentrations, 
SDS-PAGE analysis showed that no recombinant protein was expressed by the BL21 
(DE3) pLysS E. coli host cells.  The protein profiles of both the IPTG-induced and 
uninduced lysates appeared to be exactly the same. However, the positive expression 
control gene encoding the β-galactosidase fusion protein was expressed as indicated 
by the bright distinct band at its expected size range of ~121 kDa.  This band was only 
identified after IPTG induction.  No band of similar intensity was identified in the 
uninduced control lane.  The uninduced lysate served as a negative contol.  
Expression of β-galactosidase fusion protein from E. coli indicates that growth and 
induction were properly performed during the expression study.  The absence of 
expressed recombinant Tromp1 fusion protein was later confirmed by Western blot 




It was initially suspected that the tromp1 gene was perhaps cloned in the incorrect 
reading frame for transcription and translation to occur. The Geneious Pro 5.0.2. 
software was used to confirm that the gene was correctly cloned in frame with the N-
terminal peptide containing the Xpress epitope and the 6xHis fusion tag.  The start 
codon, ribosomal binding site and T7 promoter/priming site were all identified 
upstream from the polyhistidine fusion tag as expected.   
 
Secondly, the presence of rare (untranscibed) codons was ruled out.  This was based 
on a codon code usage calculator (Graphical Codon Usage Analyzer) to determine the 
compatibility between the expression E. coli and the tromp1 gene.  This was 
considered because differences in codon usage preference among organisms can lead 
to various problems that concern heterologous gene expression 
(http://gcua.schoedl.de).  
 
The presence of unexpected stop codons generated by mutation was also ruled out.  
This can especially occur when cloning PCR products.  However sequencing revealed 
the absence of such mutations. 
 
 Optimal induction conditions of the host E. coli cultures is essential in the expression 
of heterologous genes and this needs further optimization. The expression of the 
Tromp1 fusion protein in the BL21 (DE3) pLysS E. coli cells should be examined at 
different growth/induction temperatures, preferably below 37
o
C, the temperature that 
was used throughout this study.  Yin et al (2007) reported on the expression of the 
GFP-heparinaseI fusion protein in BL21 (DE3) E. coli cells examined at various 











C with an even greater amount of soluble protein observed at 15
o
C, the 
induction temperature that was used for all remaining experiments henceforth.  An 
induction temperature of 34
o
C could also be examined as was suggested in several 
protocols.  It has been suggested that by decreasing the growth or induction 
temperature, the rate at which the target protein is produced slows down and therefore 
chances of improper folding and aggregation of polypeptides decreases.  Such 
improper folding is often seen with protein overexpression in E. coli (Kataeva et al., 
2005).   However, no incubator was available of which the temperature could be 
altered.  Therefore an induction temperature of 37
o
C was used throughout this study. 
 
In addition, the IPTG-inducing concentration could be further optimized by using a 
wider range.  IPTG to a final concentration varying from 0.1 mM to 2 mM should be 
investigated.   
 
The level of protease expression in the BL21 (DE3) pLysS E. coli cells in comparison 
to the levels of expressed recombinant Tromp1 protein should be considered.  
Proteases are enzymes that catalyze the hydrolytic breakdown of proteins into 
peptides or amino acids.  To account for this, the expression experiment could in 
future be repeated in the presence of protease inhibitors to protect against different 
degrading enzymes.   
 
The BL21 (DE3) pLysS strain contains the pLysS plasmid which further carries the 
T7 lysozyme gene.  Co-expression of this T7 lysozyme gene was shown to reduce 
background expression since this lysozyme binds to the T7 RNA polymerase and by 
doing so, inhibits this enzyme before induction with IPTG occurs (Pan and Malcolm, 
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2000).  Therefore, the pLysS strain is the host of choice for expressing toxic proteins 
that could kill the E. coli cells before induction.  Unfortunately, the same lysozyme 
molecules can cause bacterial lysis during growth and continue inhibiting T7 RNA 
polymerase following induction, resulting in overall reduced protein expression levels 
(Pan and Malcolm, 2000).    Since Tromp1 is a known toxic protein (Blanco et al., 
1996), the BL21 (DE3) pLysS strain was used as the expression host for recombinant 
Tromp1 in this study. This may have resulted in inhibition of the T7 RNA polymerase 
even during induction, with as a result, undetectable levels of recombinant Tromp1 
protein.  An attempt was made to transform the tromp1 gene into BL21 (DE3) lacking 
pLysS along with the strain that contains the pLysS plasmid.  However, no growth 
was observed on the plates containing transformants lacking pLysS. This confirms the 
toxicity of Tromp1 for E. coli cells. Following this observation, expression of 
recombinant Tromp1 protein was performed in the pLysS strain during the remainder 
of the study.   
 
In future, BL21 (DE3) E. coli cells lacking the pLysS plasmid could be grown in 
medium supplemented with 1% glucose.  This would be followed by culture in 
glucose free medium for the final growth cycles.  By changing to a medium with a 
poor carbon source for these final growth cycles, higher expression levels that are 
typical of the BL21 (DE3) cells can be readily obtained following induction (Pan and 
Malcolm, 2000).  Culturing in the presence of glucose has previously shown 
decreased background expression of the T7 polymerase gene and partial improvement 
of plasmid stability in BL21 (DE3) cells (Pan and Malcolm, 2000).  This is considered 
to be the effect of catabolite repression on the lacUV5 promoter, in the λDE3 
lysogens, which drives basal expression of the T7 polymerase gene.  
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An alternative approach would be to clone the tromp1 gene as a fusion to a “carrier” 
protein for the production of soluble heterologous proteins in E. coli.  Several carrier 
proteins are available including maltose-binding protein (MBP), thioredoxin (Trx), 
glutathione S-transferase (GST), intein, calmodulin-binding protein (CBP), NusA and 
cellulose-associated protein (CAP) (Shih et al., 2002).  The choice of carrier protein 
depends on the gene to be expressed, since they do not function equally well with all 
heterologous proteins (Esposito and Chatterjee, 2006).  It has been reported that when 
used as a fusion partner to the gene of interest, the gene coding for the carrier protein 
can increase translation efficiency and promote proper folding of their partners that in 
turn leads to the enhanced solubility of the desired protein (Esposito and Chatterjee, 
2006). Some of these fusion carrier proteins play a dual role in serving as affinity tags 
as well, thus increasing the efficiency of soluble protein purification (Esposito and 
Chatterjee, 2006).   
 
Kataeva et al (2005) reported on the soluble protein expression of selected 
Shewanella oneidensis MR-1 and Clostridium thermocellum JW-20 proteins in E. coli 
(Kataeva et al., 2005).  MBP was selected as the carrier protein in their study based 
on its efficiency at improving the stability and solubility of its passenger proteins.  
This study further showed that MBP significantly increased the solubility of its 
passenger proteins following a decrease in induction temperature when compared to 
unfused variants.  This is because a decrease in induction temperature slows down 
production of the desired protein thereby allowing greater time for proper folding of 




In another study, MacDonald et al (2003) investigated the effect of N-terminal fusion 
partners on protozoan α and β tubulin gene expression levels in E. coli BL21 (DE3) 
pLysS strain.  They demonstrated that high-solubility fusion partners MBP and GST 
produce a five-fold increase in soluble protein yields when compared with the lower 
solubility fusion partner polyhistidine, the fusion partner used in the study presented 
in this dissertation (MacDonald et al., 2003). 
 
If expression of recombinant Tromp1 protein continues to fail, after having taken the 
above suggestions into consideration, an alternative method would be to obtain 
monoclonal antibodies to the various surface proteins previously identified in            
T. pallidum.  The antibody preparation would then be analysed on SDS-PAGE.  The 
most abundant antibody produced in response to treponemal infection could then be 
isolated and purified for use as capture antibodies in the immunochromatographic test 
strip for the direct detection of whole treponemes in primary lesion material.   
 
Several studies have already identified and characterized the T. pallidum outer 
membrane proteins, suggesting that they may “represent potential surface-exposed 
virulence determinants and targets of host immunity” (Blanco et al., 1997).  Norris 
and Sell have previously reported a 39 kDa polypeptide that appears to be a major 
surface constituent of T. pallidum.  They suggest that this protein may play a pivotal 
role in induction of immunity to syphilis (Norris and Sell, 1984).  In 1994, Blanco and 
colleagues had established a novel method to isolate the T. pallidum outer membrane 
and characterize its protein constituents.  Among their findings, they reported the 
identification of the 65, 31 and 28 kDa proteins.  These proteins belong to the Tromp 
family of proteins as they are exclusively associated with the outer membrane.  When 
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tested against sera obtained from rabbits inoculated with T. pallidum and from 
humans with syphilis, all three proteins proved to be antigenic.  Their significant 
enrichment in the outer membrane preparation made the Tromp proteins “leading 
candidates for membrane-spanning outer membrane proteins of T. pallidum” (Blanco 
et al., 1994).  Hence, in addition to the 31 kDa Tromp protein chosen for the purposes 
of the study presented here, these other rare outer membrane proteins could also be 
used.  
 
A second alternative method would be to harvest enough treponemes following intra-
testicular cultivation in rabbits. This would be followed by the isolation of the           
T. pallidum outer membrane.  Outer membrane isolation could be achieved using the 
method described by Blanco and colleagues whereby they harvested outer membranes 
by immersing the treponemes in 50 mM cold citrate buffer at pH 3.2 (Blanco et al., 
1994).  A more recent and gentle method for T. pallidum outer membrane isolation 
was described by Radolf and colleagues (Radolf et al., 1995).  This method is based 
upon plasmolysis of treponemes in hypertonic sucrose followed by isopycnic sucrose 
density gradient ultracentrifugation.   Isolated outer membrane fractions will then be 
sonicated on ice to release protein antigens.  After centrifugation, the supernatant 
containing soluble protein will be aspirated and subjected to SDS-PAGE and 
Coomassie blue staining and destaining as described by Laemmli (Laemmli UK, 
1970).  Protein bands of interest will be excised and eluted from the gel followed by 
purification and quantification of desired protein.   A major drawback to this approach 
is the need for several rabbits for this procedure, since only limited numbers of 
treponemes can be obtained following intra-testicular cultivation.  Secondly, the outer 
membrane of T. pallidum is extremely fragile. Therefore conventional methods used 
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for isolating outer membranes from other gram negative bacteria do not apply.  More 
gentle methods as those explained above are suggested for T. pallidum outer 
membrane isolation.  Thirdly, treponemes obtained from rabbit infection may be 
contaminated with host tissue, which can complicate the separation and purification of 
T. pallidum molecules (Blanco et al., 1994; Blanco et al., 1997). 
 
This work is part of a project that aims at designing a point-of-care test that is able to 
establish whether a patient with genital ulcer disease is infected with Treponema 
pallidum and/or Haemophilus ducreyi. Both these pathogens are nowadays rare in 
such patients and an immunochromatography test that detects both would prevent 
many patients from receiving antibiotics that are not indicated. Such a project is 
ambitious and it was obvious from the onset that this likely needed multiple 
approaches of which several would fail. This study attempted to produce sufficient 
recombinant Tromp1 protein of T. pallidum to raise antibodies to be used as capture 
antibodies in the immunochromatography strip. The method used turned out to be 
unsuccessful.  Future studies need to take this further.  Several suggestions have been 
made to increase the chances for successful production of recombinant Tromp1 
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(7.1)  Appendix A :  Preparation of PCR Reagents: 
 
1.  0.5 mM EDTA (1 L) 
     EDTA 2H2O           – 186.1 g 
     Water                      – 800 mL 
EDTA was dissolved in triple distilled water with the aid of a magnetic stirrer.  
Thereafter, the pH of the solution was adjusted to 8.0 with 20 g of sodium hydroxide 
(NaOH) pellets and the volume was brought up to 1 L.   
 
 
2.  5x TBE Buffer (1 L) 
     Trizma base                  – 54 g 
     Boric acid crystals        – 27.5 g 
     0.5 mM EDTA              – 20 mL 
All the reagents were dissolved in 800 mL of triple distilled water.  The pH of the 







3.  0.5x TBE Buffer (1 L) 
     5x TBE Buffer            – 100 mL 
     Water                           – 900 mL 
Stored at room temperature. 
 
4.  0.05% Ethidium Bromide Solution (100 mL) 
     Ethidium Bromide              – 0.05 g 
     Water                                  – 100 mL  
 
Ethidium bromide was dissolved in triple distilled water and stored at 4
o









Large gel Medium gel Small gel 
Agarose 
(molecular grade) 
3 g 1.4 g 0.45 g 
0.5x TBE buffer 
 
150 mL 70 mL 30 mL 
Ethidium bromide 
 
150 µl 70 µL 30 µL 
 




6.  Sample Loading Buffer 
 
Bromophenol blue (without xylene)                   – 0.05 g 
Sucrose                                                                – 5 g 
Water                                                                   – 20 mL  
The loading buffer was aliquoted in volumes of 1 mL into sterile 1.5 mL Eppendorfs 





(7.2)  Appendix B:  Preparation of Cloning Reagents 
 
1.  LB (Luria-Bertani) Medium  
     (1.0% Tryptone; 0.5% Yeast extract; 1.0%NaCl, pH7) 
     Bacto Tryptone                         – 10 g 
     Yeast extract                             – 5 g  
     Sodium chloride (NaCl)           – 10 g  
 
All reagents were dissolved in 800 mL of triple distilled water.  The pH of the 
solution was adjusted to 7.0 with sodium hydroxide (NaOH) and the volume was 
brought up to 1 L.  The solution was autoclaved and stored for 1 month at 4
o
C.   
 
Antibiotics were added to the medium as required as follows: 
10 µL of ampicillin (100 µg/mL in PBS) to every 10 mL volume of LB medium 
10 µL of chloramphenicol (34 µg/mL in pure ethanol) to every 10 mL volume of LB 
medium 
 
2.  LB agar plates 
LB medium was prepared as above but 15 g/L Bacto agar was added before 
autoclaving.  Immediately after autoclaving, the solution was cooled to 55
o
C in a 
waterbath.  Antibiotics were added as above and the agar solution was poured into   
10 cm plates at 20 mL volumes each.  The agar plates were allowed to harden at room 
temperature, then inverted, wrapped in foil and stored at 4
o





3.  Ampicillin Stock (100 µg/mL) 
1 g of ampicillin was dissolved in 10 mL of Phosphate buffer (pH 8.0).  The solution 
was aliquoted in volumes of 1 mL into sterile 1.5 mL Eppendorfs, covered with foil 
and stored at -20
o
C.  It was used at 100 µg/mL. 
 
4. Chloramphenicol Stock (34 µg/mL) 
0.34 g of chloramphenicol was dissolved in 10 mL of ethanol.  The solution was 
aliquoted in volumes of 1 mL into sterile 1.5mL eppendorfs, covered with foil and 
stored at -20
o
C.  It was used at 34 µg/mL. 
 
5.  IPTG Stock (238.31 mg/mL) 
0.23831 g of IPTG was dissolved in 1 mL of triple distilled water.  The solution was 




























(7.3)  Appendix C:  Optimization of Sequencing Reaction 
 
The primers used for the PCR reaction were initially used for the cycle sequencing 
reaction as well.  The primers were diluted to a final concentration of 3.2 pmol/µL.  
However, the use of these primers failed to provide any sequencing signal for analysis 
after several attempts.   
 
In a first attempt to optimize the sequencing reaction, the primers were further diluted 
to a final concentration of 2.5 pmol/µL, to facilitate primer binding as suggested by a 
colleague.   It has been suggested that an increased primer concentration such as      
3.2 pmol/µL may require that the annealing temperature (cycle sequencing reaction) 
be increased as well.  It was therefore decided to lower the primer concentration to 
accommodate for the average annealing temperature.  However, this also failed to 
provide sequencing signal.   
 
A second attempt at optimization investigated the ABI Prism Big Dye Kit to ensure 
that it was in working order.  The same kit was used to sequence a colleague’s 
samples other than that being investigated and this proved to be successful.   
 
The conditions of the sequencer where then optimized.  Its ramp rate was decreased to 
allow the primer enough time to bind to the template DNA.  The annealing 
temperature was also increased but neither of these attempts proved successful.   
 
Finally, the primers used in the reaction were  investigated.  It had been suggested that 
the primers were initially too long (30 to 35 base pairs).  In addition, both primers 
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contained a high GC content with the forward primer having an even greater GC 
content after the addition of the CACC nucleotide overhang (the requirements for 
directional cloning).  Taking the above into consideration, it was therefore decided to 
redesign these primers for the sequencing reaction.    
 
In one set of primers, the restriction sites and the CACC nucleotide overhang (forward 
primer) on the initial PCR primers were simply removed: 
 
Forward Sequencing primer:  5’-ATTCGGTAGCAAGGATGCCGCA-3’ 
Reverse Sequencing primer:  5’-CTAGCGAGCCAACGCAGCAAC-3’ 
 
 
A second set of primers were designed to a sequence internal to the primers on either 
end of the insert: 
 
Forward Sequencing primer:  5’-CATGATAGCGGATGCTGTC-3’ 
Reverse Sequencing primer:  5’-AACAACTCGCCTCCAAT-3’ 
 
The new sequencing primers were reconstituted according to the manufacturer’s 
instructions and diluted to a final concentration of 3.2 pmol/µL.  Both newly designed 
primer sets successfully produced sequencing data and were used for all sequencing 











(7.4)  Appendix D:  Preparation of Lysis Buffer   
         (50 mM Tris-HCl; 10% glycerol; 0.1% Triton X-100) 
 
 
For 100 mL: 
500 mM Tris-HCl, pH 8.0 (autoclaved)                         – 10 mL  
Glycerol                                                                          – 10 mL  
Triton X-100                                                                   – 0.1 mL  
 






Lysis Buffer additives: 
 
The following additives were included in the lysis buffer only when ready to use. 
 
To every 10 mL of lysis buffer the following were added: 
10 mg/mL Lysozyme                                                                              – 100 µL  
10 mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitor       – 100 µL 
Protease cocktail                                                                                     – 1µL  
 
Lysozyme Stock (10 mg/mL) 
0.01 g of lysozyme was dissolved in 1 mL of triple distilled water and kept on ice at 







(7.5)  Appendix E:  Preparation of SDS-PAGE Solutions 
 
1.  3% Agarose  
     Agarose                      – 3 g 
     Water                         – 100 mL 
The agarose was added to triple distilled water and allowed to dissolve by heating in a 
microwave.   
 
2.  30% Acrylamide mix 
     Acrylamide                  - 60 g 
     Bisacrylamide              - 1.6 g  
     Water                           - 200 mL  
The arylamide and bisacrylamide was dissolved in triple distilled water.  The solution 




3.  4x Separating gel buffer (1.5 M Tris-HCl, pH 8.8) 
     Tris                             – 36.3 g 
     Water                          – 150 mL  
Tris was dissolved in triple distilled water and its pH was adjusted to 8.8 with HCl.  









4.  4x Stacking gel buffer (0.5 M Tris-HCl, pH 6.8) 
     Tris                             - 3 g 
     Water                          - 50 mL 
Tris was dissolved in triple distilled water and its pH was adjusted to 6.8 with HCl.  




5.  10% SDS 
      SDS                           – 10 g 
      Water                         – 100 mL 
SDS was dissolved in triple distilled water and stored at room temperature.  A mask 
was worn when handling SDS. 
 
6.  10% Ammonium Persulfate (NH4)2S2O8 
     Ammonium Persulfate     - 0.1 g 
     Water                               - 1 mL 
Ammonium persulfate was dissolved in triple distilled water.  Ammonium persulfate 
solution had to be made up fresh before use.   
 
7.  20% Ethanol overlay 
    Ethanol                           – 20 mL 
    Water                              – 80 mL 





8.  10x Electrode Buffer (0.25 M Tris-HCl; 1% SDS; 1.92 M Glycine) 
      Tris                                   – 3.028 g 
      Glycine                            – 14.413 g 
      SDS                                 – 1 g 
      Water                               – 1000 mL 
 
Tris and glycine were dissolved in 500 mL of triple distilled water.  SDS was then 
added to the solution without swirling since SDS is extremely foamy.  Instead the 
solution was allowed to heat in a waterbath for a few minutes until the SDS was 




9.  Rapid Staining Fixing Solution (25% isopropanol; 10% acetic acid) 
    Isopropanol                          – 250 mL 
    Acetic acid                           – 100 mL 
    Water                                   – 750 ml 










10.  Coomassie Blue Staining Solution (0.06% Coomassie Blue; 10% acetic acid) 
     Coomassie Blue R250 dye       - 0.6 g 
     Acetic acid                               - 100 mL 
     Water                                       - 900 mL 
The Coomassie blue dye was dissolved in acetic acid and the solution was brought up 
to 1 L with triple distilled water.  The staining solution was stored at room 
temperature.   
 
 
11.  Destaining Solution (7% acetic acid; 5% methanol) 
     Acetic acid                            - 70 mL 
     Methanol                               - 50 mL 
     Water                                     - 880 mL 













12.  2x SDS-PAGE Sample Loading Buffer 
      0.5 M Tris-HCl, pH 6.8         – 2.5 mL  
      Glycerol (100%)                    – 2 mL 
      β-mercaptoethanol                 – 0.4 mL 
      Bromophenol blue                 – 0.02 g 
      SDS                                        – 0.4 g 
All reagents were combined and brought to a final volume of 10 mL with triple 
distilled water.  The solution was aliquoted and stored at -20
o
C until needed.   
 
 
13.  1x SDS-PAGE Sample Loading Buffer 
      0.5 M Tris-HCl, pH 6.8       – 1.25 mL 
      Glycerol (100%)                  – 1 mL 
      β-mercaptoethanol               – 0.2 mL 
      Bromophenol blue               – 0.01 g    
      SDS                                     – 0.2g 
All reagents were combined and brought to a final volume of 10 mL with triple 
distilled water.  The solution was aliquoted and stored at -20
o















14.  Gel preparation for SDS-PAGE 
 
Reagents Large gel Small gel 
Distilled water 13.4 mL 4 mL 
30% Acrylamide mix 16 mL 3.33 mL 
1.5 M Tris-HCl, pH 8.8 10 ml 2.5 mL 
10% SDS 400 µL 100 µL 
10% Ammonium persulfate 200 µL 50 µL 
TEMED 40 µL 5 µL 
Total volume 40 mL 10 mL 
 




Reagents Large gel Small gel 
Distilled water 12.2 mL 3 mL 
30% Acrylamide mix 2.6 mL 670 µL 
0.5 M Tris-HCl, pH 6.8 5 mL 1.25 mL 
10% SDS 200 µL 50 µL 
10% Ammonium persulfate 100 µL 25 µL 
TEMED 20 µL 2 µL 
Total volume 20 mL 5 mL 
 







(7.6)  Appendix F:  Preparation of Western Blot Reagents 
 
1.  Towbin Transfer buffer (1 L) 
     (20 mM Tris; 192 mM glycine; 20% methanol; pH 8.3) 
     Water                                                       – 800 mL  
     Tris                                                          – 2.4 g 
     Glycine                                                    – 14.4 g 
     Methanol                                                  – 200 mL  
The reagents were dissolved in 800 mL of triple distilled water and the pH was 
adjusted to 8.3.  The buffer was stored at 4
o
C.   
 
2.  Ponceau S Solution (0.1% Ponceau; 1% Acetic acid) 
     Ponceau S stain powder                         - 0.1 g 
     Acetic acid                                             -  1 mL 
     Water                                                      - 50 mL 
The Ponceau S stain powder and acetic acid were dissolved in 50 mL of triple 
distilled water whilst placed on a stirrer bath.  Thereafter the volume of the solution 









3.  Blocking buffer (PBSTM) 
    1x PBST                                                 – 100 mL 





4.  Wash buffer (PBST) 
     (1xPBS containing 0.1% Tween-20) 
     1x PBS                                                   – 100 mL 



































(7.7)  Appendix G:  Preparation of ELISA Reagents 
 
1.  Coating Buffer (Bicarbonate Buffer) 1 L 
     Water                                               – 900 mL 
     Sodium carbonate (Na2CO3)           – 5.3 g 
     Sodium Bicarbonate (NaHCO3)      – 4.2 g     
The Na2CO3 and NaHCO3 were dissolved in 900 mL of triple distilled water.  The pH 
of the solution was adjusted to 9.6 and brought up to a final volume of 1 L with triple 




2.  1x Phosphate buffered saline/Tween-20 (PBST) Wash buffer 
Ten phosphate buffered saline tablets were dissolved in 1 L of triple distilled water for 
the preparation of 10x PBS.  The solution was sterilized by autoclaving.   A 10 mL 
volume of 10x PBS was diluted with triple distilled water to make up 100 mL of      
1x PBS.  For every 100 mL of 1x PBS, 10 µL (0.01%) of Tween-20 was added.  The 
solution was stored at 4
o











3.  Blocking buffer 
     Water                                                      – 900 mL 
     Sodium carbonate (Na2CO3)                  – 5.3 g 
     Sodium Bicarbonate (NaHCO3)             – 4.2 g 
     Non-fat dry milk powder                        – 50 g 
All reagents were dissolved in 900 mL of triple distilled water.   The pH of the 
solution was adjusted to 9.6 and the volume of the solution was brought up to 1 L 




4.  Primary and Secondary Antibody diluent  
     PBS/Tween-20                                       – 100 mL 





























(7.8)  Appendix H:  Conversion of Centrifuge “rpm” values to “g” values 
 
R        =  radius (in millimeters) 
N        =  speed (in r.p.m.) divided by 1000 
RCF   =  gravitational acceleration “g” 
 
Primary Calculations: 
RCF (x g)   = 1.118 R.N
2 
Speed (r.p.m.) = 946RCF/R 




RCF = 1.12 x 185 mm x (17000rpm divided by 1000) x (17000rpm divided by 1000) 
           = 1.12 x 185 mm x 17 x 17 
           = 59,881 x g 
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